',6&/2685(
5('$&7('67$7,67,&$/$1$/<6,63/$1
$%,16&/
$3+$6(,,,5$1'20,=('23(1/$%(/&526629(508/7,&(17(5
6$)(7<$1'()),&$&<678'<72(9$/8$7(1$%3$&/,7$;(/
$%5$;$1(ÂŠ$60$,17(1$1&(75($70(17$)7(5,1'8&7,21:,7+1$%
3$&/,7$;(/3/86&$5%23/$7,1,16 8%-(&76:,7+648$0286&(//121
60$//&(///81*&$1&(516&/&
7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG 
&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFD OWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH /DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HO JHQHÂ¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLS OHV

x5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQI RUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOF RPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV
x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW

,QIRUPDWLRQDERXW&HOJHQHÂ¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFD OWULDOVFOLQLFDOWULDOVGDWDVKDULQJ

&(/*(1([ZIP_CODE],(7$5<,1)250$7,211$%1$%
//121//121
GQRWEHVKDQRWEHVK
HDUFKHUVDQGDUFKHUVDQ
GUHJXOHJXODWLRQDWLR
OHJDORUFJDORUFRQWRQ
WHGWRFHUWDLQHGWRFHU
HUWDLQLQIRUPHUWDLQLQIRUP
WHFW&HOJHQHHFW&HOJHQ
QJSULQFLSOHQJSULQFLSOH
JUH\JUH\VSDFHVSDFH
HQWLILHQWLILFDWLRQFDWLRQ
WDLQFRQILGHDLQFRQILG
RQWDLQLGHQWRQWDLQLGHQ
\DOVRPD\F\DOVRPD\
KHVLVJHQHUDKHVLVJHQH
VHDWWDFKPHVHDWWDFK
RG\RIWKHUHG\RIWKHUH
ERXW&HOJHQERXW&HOJHQ
RIWKDWLQIRUPIWKDWLQIR
LRQDERXWRXRQDERXWR
DWLRQDERXWDWLRQDERXW
RXQGDWKWWSRXQGDWKWWS
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 1STATISTICAL ANALYSIS PLAN
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTI-CENTER, SAFETY AND 
EFFICACY STUDY TO EVALUATE NAB -PACLITAXEL (ABRAXANEÂ®) AS 
MAINTENANCE TREATMENT AFTER INDUCTION WITH NAB -PACLITAXEL PLUS 
CARBOPLATIN IN SUBJECTS WITH SQUAMOUS CELL NON-SMALL CELL LUNG 
CANCER (NSCLC)
STUDY DRUG: nab-Paclitaxel (AbraxaneÂ®)
PROTOCOL NUMBER: ABI-007-NSCL-003
DATE FINAL: 19MAY-2017
Prepared by:
[CONTACT_193009]
[ADDRESS_833326] be 
informed that the information is confidential and may not be further 
disclosed by [CONTACT_476].&(/*(1The infThe inf1(35235on bon
CelCel
and, nd, 1(1
(/5,(7$5<,1)250$7,21US US 
LUNG UNG 
pared by[CONTACT_625535] ::
(/35
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833327] an ...............................................................................13
4.2. Study Endpoints .....................................................................................................13
4.2.1. Primary Endpoint ....................................................................................................13
4.2.2. Secondary Efficacy  Endpoint s ................................................................................13
4.2.3. Secondary Safety Endpoints ...................................................................................14
4.2.4. Exploratory Endpoint(s) ..........................................................................................14
4.3. Stratification, Randomization, and Blinding ............................................................14
4.3.1. Induction Part .........................................................................................................14
4.3.2. Randomization and Main tenance Pa rt.....................................................................15
4.3.3. Follow-up Pe riod....................................................................................................15
4.4. Sample Size Deter mination .....................................................................................15
5. GENERAL STATISTICA L CONSIDERA TIONS .................................................17
5.1. Reporting Conventions ...........................................................................................17
6. PROTOCOL DEVIATIONS/VIOLATIONS ..........................................................[ADDRESS_833328] ory......................................................................................................21&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ADDRESS_833329] ioion Pn P
StudyStudy Py
2.2. BaBa
7.2.3..2.3
2.4.24
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833330] ical Approaches for Control of Alpha ............................................................56
8.3. Probability of Clinically Meaningful PFS Effects Given the Interim Data ...............57
8.4. Conditional Power at the Interim Analysi s for PFS .................................................57
8.5. Conditional Power at the Interim Analysi s for OS ...................................................59
9. CHANGES TO THE STATISTICAL ANALYSES SECTION OF THE
PROTOCOL...........................................................................................................61
10. REFERENCES.......................................................................................................62
11. APPENDICES ........................................................................................................6322
.......343
..............343
.........................
..........................
..........................
..........................
..........................
..................
.........................
..........................
ureure............
......................
.......................
Efficacy EnEfficacy En
.......................
nalysisnalysis ....
.................
M ANALYSANAL
al Informaal Informa
tatitiststical ical AA
ProbabilProbabil
ConCo
.5..5.
9
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 411.1. Study schematic ......................................................................................................63
11.2. Handling of Dates ...................................................................................................63
11.2.1. Calculation Using Dates .........................................................................................64
11.3. Date Imputation Guideline ......................................................................................65
11.3.1. Impute Missing Dates for Adverse Events/ Prior or Concomitant 
Medications............................................................................................................65
11.3.2. Impute Missing Dates for Medical Hi story ..............................................................66
11.4. Tumor Respons e Windows .....................................................................................66
11.5. MedDRA Versions  and D ates.................................................................................67
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21..6666
............... 6666
.......................... 6
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833331] OF TABLES
Table 1: Abbreviations and Specialist Terms ..........................................................................8
Table 2: Calculation of Induction Dosing Period for Each Study Drug Based on Cycle 
Day Number of Last Dose of the Study Drug..........................................................24
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
5
3523
(1(3
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 7Signature{See appended electronic signature [CONTACT_3264]}
Printed Name [CONTACT_1782]
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833332] OF ABBREVIATIONS
Table 1: Abbreviations and Specialist Terms
Abbreviation Meaning
ADT Analysis date
AE Adverse eventAESI Adverse event of special interestALT Alanine aminotransferase (SGPT)ANC Absolute neutrophil countANOVA Analysis of varianceAST Aspartate aminotransferase (SGOT)AUC Area under the curveBMI Body mass indexBSA Body surface areaBSC Best supportive careCI Confidence intervalCMH Cochran-Mantel-HaenszelCR Complete responseCRF Case report formCT Computerized tomographyCTCAE Common Terminology Criteria for Adverse EventsDCR Disease control rateDMC Data Monitoring CommitteeECOG Eastern Cooperative Oncology GroupEOS End of studyEQ-5D-5L EuroQol 5-dimensional quality of life instrumentFNC Fine cell cytologyHgb HemoglobinHR Hazard ratio
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21l
mm
zed tomogrzed tomogr
mon Terminmon Term
Disease contsease con
Data MData 
EaEa
QQ-5D--5D-5L5L
FNCNC
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833333] error SGOT Serum glutamic oxaloacetic transaminase (AST)SGPT Serum glutamic pyruvic transaminase (ALT)SMQ Standardized MedDRA querySOC System organ classSTDEV Standard deviation
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21blee
aluation critluation c
adverse evedverse eve
atistical analatistical an
Stable disStable dis
Stantan
TT
SMQSM
C
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833334] Upper limit of normalUE UnevaluableUS [LOCATION_002]VAS Visual analog scaleWBC White blood cellWHO World Health Organization 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 112. INTRODUCTION
This statistical analysis plan (SAP) describes the analyses and data presentations for Celgeneâ€™s 
protocol ABI-007-NSCL-003 â€œA PHASE III, RANDOMIZED, OPEN-LABEL, MULTI-
CENTER, SAFETY AND EFFICACY STUDY TO EVALUATE NAB -PACLITAXEL 
(ABRAXANEÂ®) AS MAINTENANCE TREATMENT AFTER INDUCTION WITH NAB -
PACLITAXEL PLUS CARBOPLATIN IN SUBJECTS WITH SQUAMOUS CELL NON-
SMALL CELL LUNG CANCER (NSCLC)â€ which was issued on 27SEP2013 and amended on 
28OCT2014, 07MAY2015 and 13MAR2017. It contains definitions of analysis populations, derived variables and statist ical methods for the analysis of efficacy and safety.
These analyses include all the dry runs described in the Scope of Work, the non-inferential and 
non-binding interim analyses described in the protocol, and the final analysis for the clinical study report. The interim analyses will be performed by a different vendor. Throughout this SAP, 
for the Induction Part, the treatment arm will be referred to as the nab-Paclitaxel/carboplatin 
treatment, while in the Maintenance Part, the treatment arms will be referred to as the nab-
Paclitaxel+BSC (referring to nab-paclitaxel plus best supportive care) and BSC (referring to best 
supportive care) arms. The purpose of the SAP is to ensure the credibility of the study findings 
by [CONTACT_094]-specifying the statistical approaches to the an alysis of study data prior to database lock 
and any data analysis for the first inferential in terim analysis. This SAP is developed after the 
finalization of the protocol and will be finalized and signed [ADDRESS_833335] infere ntial interim analysis. All statistical analyses detailed in this SAP will be 
conducted using SASÂ® Version 9.2 or higher. Th e clinical cutoff date will be determined based 
on the occurrence of approximately 91 progression-free survival (PFS) events for the first non-
binding interim analysis and approximately 136 PFS events for the final PFS analysis and interim overall survival (OS) analysis. The clinical cutoff for the final OS analysis will occur at 
147 deaths, which is approximately 1.5 years after the final PFS analysis.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21on on 
ns,ns
ferentferent iaal anl an
r the clinicar the clinic
Throughout hroughout 
clitaxel/carblitaxel/carb
ferred to aserred to a
e)and and BSCBSC
edibilitdib y yofof
tudytudy data pdatyy
is. This SA. This SA
ned d 4 weeks4 wee
stticicala analyanalyl
clinical clinical cuu
ionon--free sufree s
36 36 PFS evPFS ev
e clinical cue clinical c
5 yyears afterears afte
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 123. STUDY OBJECTIVES
3.1. Primary Objective
The primary objective of the study is to evaluate progression-free survival (PFS) with nab-
paclitaxel as Maintenance treatment after response or stable disease (SD) with nab-paclitaxel 
plus carboplatin in subjects with squ amous cell non small-cell lung cancer (NSCLC).
3.2. Secondary Objectives
The secondary objectives of the study are:
!To evaluate the safety and tolerability of nab-paclitaxel as Maintenance treatment after 
response or SD with nab-paclitaxel plus carboplatin in subjects with squamous cell 
NSCLC.
!To further assess the efficacy with nab-paclitaxel as Maintenance treatment after 
response or SD with nab-paclitaxel plus carboplatin in subjects with squamous cell 
NSCLC, as measured by [CONTACT_625536].
3.3. Exploratory Objectives
The exploratory objectives of the study are:
!To determine baseline tumor characteristics which predict response and resistance to nab-
paclitaxel/carboplatin during the Induction Part of the study.
!To determine what changes in peripheral tumor characteristics during treatment are 
associated with acquisition of resistance in the subjects who had initial clinical benefit.
!To assess healthcare resource utilization during the Maintenance Part of the study.
!To assess the Lung Cancer Symptom Scale (LCSS) and EuroQol Group 5-Dimension 
Self-Report Questionnaire score (EQ-5D-5L).
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21eatmatment afent af
quamous ceuamous c
cecetreatmtreatm en
cts with squs with sq
cs which prcs which p
ioon Partn Part ofof
pheral tumopheral tum
sistance in sistance i
e utilizatutilizat ioi
ncer Symptocer Sympto
nnannaire scoreire sc
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833336]
supportive care (BSC) or BSC alone as Maintenance treatment after response or SD with nab-
paclitaxel plus carboplatin as Induction in subjects with squamous cell NSCLC. Approximately 
450 subjects with Stage IIIB/IV squamous cell NSCLC eligible to receive standard treatment of 
nab-paclitaxel plus carboplatin for [ADDRESS_833337] has a radiolog ically assessed complete response (CR), partial 
response (PR), or SD without clinical progression, they will be randomized (2:1) in the 
Maintenance Part of the study to receive nab-paclitaxel plus BSC or BSC alone. BSC is defined 
as the best palliative care per investigator (including but not limited to: antibiotics, analgesics, 
antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal 
external-beam radiation for control of pain, cough, dyspnea, or hemoptysis) excluding antineoplastic agents. Approximately [ADDRESS_833338] 1.1 
guidelines or death.
4.2.2. Secondary Efficacy Endpoints
[IP_ADDRESS]. Secondary Efficacy Endpoints
Secondary efficacy endpoints specified in the protocol include the following:
!Overall survival (OS) from randomization into the Maintenance Part of the study
!Overall response rate (ORR) during the Induction and Maintenance Parts of the study
based on investigator assessment according to RECIST 1.1 guidelines
[IP_ADDRESS]. Other Secondary Efficacy Endpoints
!PFS from Day 1 Cycle 1
!OS from Day 1 Cycle 1
!ORR in Maintenance Part beyo nd response in Induction Part
!Disease control rate (DCR) during the Induction Part and over the entire study&(/*(1([ZIP_CODE],(7$5<,1)250$7,21y y
nt of t of 
tudyudy. If If
artial rtial 
n the n the 
BSC iBSC i s desd e
otics, analgotics, analg
port, and/orport, and/or
ysis) excludysis) excl
fororththe prime pri
randomizarandomiz
ased on invased on inv
EndpointEndpoint ss
cacy Endpacy End
dpodpointints specpe
vival vival (OS) (OS) 
l response response
d on invesd on inves
2..Otherthe
!PFS fPFS 
!O
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 14!Time to response during the Induction Part and over the entire study, with and without 
the requirement of confirmation of response
!Duration of response over the entire study, with and without the requirement of 
confirmation of response
4.2.3. Secondary Safety Endpoints
Safety parameters such as AE and SAEs.
4.2.4. Exploratory Endpoint(s)
!Healthcare resource utilization during the Maintenance Part of the study using a 
questionnaire including hospi[INVESTIGATOR_602], emergency room visits, doctor or nurse visits, procedures, and/or additional medication. 
!Change in the LCSS and EQ-5D-5L.
The following exploratory endpoints will be described in a separate SAP:
!The correlation between pretreatment tumor characteristics and response and resistance to 
the study treatment determined using next-generation sequencing methods, immunohistochemistry, or other analysis methods. 
!The association between the changes in tumor characteristics and the acquisition of 
resistance to therapy from plasma samples taken at treatment failure during Maintenance. 
!The association between DNA nucleotide polymorphisms in subjectâ€™s germ line DNA 
and association with treatment efficacy and toxicity. 
4.3. Stratification, Randomization, and Blinding
4.3.1. Induction Part
The Induction Part of the study is a one-arm, open label run-in period of nab-paclitaxel plus 
carboplatin that runs for four cycles (approximately 21 days per cycle). The main purpose of the 
Induction Part is to identify those subjects who are eligible for randomization in the Maintenance 
Part of the study. Approximately [ADDRESS_833339] treatment with nab-paclitaxel 
plus carboplatin for 4 cycles will be enrolled, provide d if all inclusion/exclusion criteria are met 
within a 28-day screening period prior to Cycle 1 Day 1.
Induction treatment will comme nce on Cycle 1 Day 1:
!nab-Paclitaxel 100 mg/m2IV infusion over 30 minutes on Days 1, 8, and 15 of each 
21-day cycle
!Carboplatin AUC = 6 mg*min/mL IV on Day [ADDRESS_833340] has radiological or clinical PD, they will be discontinued from the study and their 
death dates will be provided if possible.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21a a 
nurse visitnurse visit
AP::
and responand respo
quencing mquencing m
aracteristracterist ic
en at treatmen at treatm
polymorphpolymorp
anand toxid toxi cici
zatiozatio n,n,a
yyiiys a ones a one --a
ur cycles (ar cycles (
ify thosify thos e sue
proximatelyroximate
r 4 cyr 4 cy cles wcles w
screening screening 
eatmeatm ent wient wi
!nabnab--PaPa
2121--d
!!
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833341] has a radiologically assessed 
CR, PR, or SD without clinical progression, he/she will be evaluated for eligibility for the 
Maintenance Part. Subjects (approximately 216) who satisfy all inclusion/exclusion criteria will be randomized 2:1 to receive either:
!nab-Paclitaxel 100 mg/m
2IV infusion over 30 minutes on Days 1 and 8 of each 21-
day cycle plus BSC until disease progre ssion (for guidelines on starting dose for 
Maintenance Part of the study if the subject had dose reduced  during the Induction 
Part of the study see Section 8.3 of protocol ABI-007-NSCL-003 dated DD Feb 2017)
OR
!BSC until disease progression 
Maintenance therapy should start at the time of randomization. If this is not possible, a maximum 
of [ADDRESS_833342] start Maintenance therap y no earlier than 21 days and no later than 35 
days from Day 1 of the fourth cycle of Induction therapy. 
Randomization will be stratified by [CONTACT_123573] (IIIB vs IV), response in Induction (CR/PR vs 
SD), and Eastern Oncology Cooperative Group (ECOG) performance status (0 vs 1). 
In cases where there is a stratification error at randomization, then the actual stratum from the 
CRF will be used for the final analysis. 
A pooling algorithm will be employed to eliminate small stratums. Please refer to Pooling 
Algorithm for Eliminating Small Stratums in Section [IP_ADDRESS] .   
4.3.3. Follow-up Period
All subjects who discontinue from the Maintenance Part of the study for any reason other than 
withdrawal of consent, lost to follow-up, or d eath, will enter the Follow-up period that will have 
a visit [ADDRESS_833343] ratio (HR) of 0.60 for PFS 
improvement with the nab-paclitaxel plus BSC regimen over the BSC alone regimen. There is an 
80% power to detect a hazard ratio of 0.[ADDRESS_833344] conducted at the 5% level of 
significance. This hazard ratio of 0.60 assumes an underlying exponential distribution for both 
treatment groups with a median time to PFS of 2 months for the BSC alone group and a median 
time to PFS of 3.33 months for the nab-paclitaxel plus BSC group. Hen ce, the final analysis will &(/*(1([ZIP_CODE],(7$5<,1)250$7,212017017))
ossible, a mossible, a m
ffMaintenaMaintena
and no land no at
sponse in Inonse in I
ormormance staance 
on, then th, then th
small stratsmall stra
cttion ion [IP_ADDRESS].
MaintenanMaintenan
w--up, or deup, or d
or discontor discont ini
ion will conion will co
gression of ession of
very very 90 dayda
a total of 1a total of 
mple Sizemple Size
zes for this for thi ss
aryryPFS evePFS eveyy
e MaintenaMaintena
improvememproveme
80% po0% po
ni
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 16be conducted after 136 PFS events (ie, events of disease progression or deaths from any cause) 
have occurred.
The final analysis of the primary endpoint will be performed when approximately [ADDRESS_833345] been observed. A total of approximately 216 subjects will need to be randomized assuming an approximate 36 months accrual period and an approximate 2 months follow-up and 
an approximate 9% per month dropout rate.
The required number of PFS events and power calculation were obtained from  
Approximately up to 450 subjects will be enrolled in the Induction part of the study. This sample 
size woul d provide approximately 216 sub jects eligible for randomization in the Maintenance 
part.   
In the nab-Paclitaxel Phase 3 NSCLC development study (Protocol CA031), 42% (13/31) and 
63% (125/198) of the squamous subjects from the North American and ex-North American sites, respectively, were progression free after 4 cycles of treatment and remained in the study in Cycle 
5 and beyond. It is assumed that approximately 50% (225/450) of the subjects in the Induction 
part of this study will meet the radiologic and clinical progression free criteria at the end of Cycle 4. Furthermore, it is expected that approximately 4% of these 225 subjects will not meet 
the other inclusion/exclusion criteria for the Maintenance part, yielding a total of approximately 
216 subjects entering the Maintenance part of the study.
The actual number of subjects enrolling into the  Induction part, and then being randomized in the 
Maintenance part of the study will be monitore d on an ongoing basis and adjusted accordingly to 
ensure that the targeted number of required PFS events for the Maintenance part is attained. Enrollment of the Induction part, therefore, could be discontinued early or extended beyond the 
planned number of 450 subjects.  
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21sasample mple 
enance enance 
2% (13/31) % (13/[ADDRESS_833346]
subjects in tubjects in
ee crie criteriteriiia
ese e 225subsu
, yielding a, yielding
ion opart,part, anan
aan ongoingn ongoin
eventsvents for tr
uld be disculd be disc
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833347] 
operating procedures.
5.1. Reporting Conventions
The following reporting conventions apply ge nerally to tables, listings, and figures:
!The study part will be included as a column in the listings where applicable.
!Data from all study centers will be combined for analysis;
!All stratified efficacy analyses will us e the stratification factors for randomization
(disease stage (IIIB vs IV), response in Induction (CR/PR vs SD), and ECOG performance status at randomization (0 vs 1));
!All statistical te sts of the treatment effect will be interpreted based on the stoppi[INVESTIGATOR_625526]-specified interim analyses; P-values will be rounded to 4 decimal places. P-values that round to 0.0000 will be presented as â€˜<0.0001â€™ and p-values that round to 1.0000 w ill be presented as â€˜> 0.9999â€™; 
!Confidence intervals (CIs) will be presented as 2-sided 95% CIs unless specified 
differently for a given analysis;
!Summary statistics will consist of the number and percentage of subjects (or cycles, if 
appropriate) in each category for discrete variables, and the sample size, mean, 
median, standard deviation, minimum, and maximum for continuous variables;
!All mean and median values will be formatted to one more decimal place than the 
measured value. Standard deviation values will be formatted to two more decimal places than the measured value. Minimum and maximum will be formatted to the 
same decimal place as the measured value.
!All percentages will be rounded to one decimal place. The number and percentage of 
responses will be presented in the form XX (XX.X%), where the percentage is in the parentheses;
!All listings will be s orted for presentation in order of randomized tr eatment arm, 
study center, subject, and date of procedure or event. Subjects who are not randomized will be listed as a non-randomized group before randomized subjects;
!All analysis and summary tables will have the analysis population sample size (i.e., 
number of subjects)
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ndomizatndomizat ioi
and andECOGCOG
d based on based on
ues will be s will b
presented apresented 
0.9999â€™; 0.9999â€™; 
s 2-s 2sided 9sided 9
number andnumber and
crete varicrete vari a
mummum , and mand m
will be forwill be fo
deviatdeviat ioin v
ed valuevalue . M. M
as the meaas the mea
will be rouwill be ro
ll be presenll be pres
es;es;
ttings will bings will 
udyycencenyy ter, ter,n
randoando mizemize
!!All Allanan
numnum
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 186. PROTOCOL DEVIATIONS/VIOLATIONS
The protocol deviations/violations will be id entified and assessed by [CONTACT_625537]. Protocol deviations and 
violations will be reviewed before database lock to determine the per protocol population 
(defined in Section [IP_ADDRESS] for the Maintenance Part of the study). Events that could trigger 
exclusion from the per protocol population include inclusion/exclusion criteria violations, failure 
to take any study drug as assigned, randomization errors, and prohibited concomitant 
medications and procedures.
The protocol deviations/violations will be summarized separately by [CONTACT_625538]. A by-subject listing of subjects with protocol violations in the ITT population will be 
provided.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21the ITT the ITT 
ulatulatioion will n wil
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833348] Disposition
The total number of subjects screened will be presented, and subjects with screen failure and 
reasons for screen failure will be summarized by [CONTACT_625539].
The number of subjects in Induction ITT and Sa fety populations will be presented with 
percentages based on the number of subjects in the ITT population. 
The number of subjects who are randomized to the Maintenance Part as well as the number who 
are not randomized to the Maintenance Part w ill be presented. Of those who are not ra ndomized, 
the number of subjects who do not screen fail but never receive treatment, along with the number 
of treated subjects discontinue treatment duri ng the Induction Part and reasons for treatment 
discontinuation will be summarized for all subjects who are deemed eligible for the study with the following categories:
!Death
!Adverse event
!Progressive disease
!Symptomatic deterioration
!Withdrawal by [CONTACT_1130]
!Lost to follow-up
!Study terminated by [CONTACT_3211]
!Protocol violation
!Other
Reasons for study discontinuation will be summar ized for all subjects who sign informed consent 
and discontinue study during the Inducti on Part with the following categories:
!Screen failure
!Death
!Adverse event
!Withdrawal by [CONTACT_1130]
!Lost to follow up
!Protocol violation&(/*(1([ZIP_CODE],(7$5<,1)250$7,21d 
ber of r of 
d with with 
ell as the null as the nu
who are nowho are 
ment, alongment, alon
and ran easoeaso
emed eligibemed e
by[CONTACT_625540]
!!Deatea
!!AA
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 20!Other 
The size of following analysis populations for the Maintenance Part w ill be su mmarized based 
on number of subjects randomized in the Maintenance Part:
!ITT Population
!Response Evaluable Population
!Safety Population
!PP Population
Subjects discontinuing the Maintenance treatmen t will be summarized as well as reasons for 
treatment discontinuation. Subjects who discontinue from the study during the Maintenance Part
will be summarized as well as reasons  for study discontinuation. 
Finally, the number of subjects who discontinue Maintenance and enter into the follow up part of 
the study will be summarized by [CONTACT_625541].
Listings will be provided for discontinued subjects with reason for treatment and study 
discontinuation.
7.2. Induction Part
7.2.1. Study Population Definitions
[IP_ADDRESS]. Intent-to-Treat Population
The efficacy analysis will be performed on the ITT population, which includes all enrolled 
subjects who received at least [ADDRESS_833349] has any efficacy assessments collected.
[IP_ADDRESS]. Safety Population
The safety population will be the analysis population for all safety/ tolerability analyses. The 
safety population in cludes all subjects e nrolled who received at least [ADDRESS_833350] dose of administration of nab-paclitaxel or carboplatin. If multiple values are present for 
the same date, the average of these values will be used as the baseline.
7.2.3. Demographics
Demographics will be summarized for the ITT population. Age (years) and weight (kg) at 
baseline will be summarized descriptively. Age category (<65 versus â‰¥65 years, <70 versus â‰¥70 &(/*(1([ZIP_CODE],(7$5<,1)250$7,21ons for ons for 
intenance Pntenance
o the foo the fo llolloww
who arho ar e rane
or treatmentreatmen
onnththe ITT pe ITT p
f study studyf  trearey
l be the anae the ana
des all subjdes all sub
clear documear docum
e safete safet y y poppo
Baseline vaBaseline va
Induction PI[INVESTIGATOR_625527] o
e same sam e datee dat
.2.3..2.3.
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 21years, and < 75 versus â‰¥ 75 years), sex, race, and ethnicity will be summarized by [CONTACT_444688].
Age will be calculated as follows: age = greatest integer âˆ€[(date of informed consent â€“ date of 
birth + 1) / 365.25]. 
7.2.4. Baseline Characteristics
Baseline characteristics, the latest collected on or before the first date of dosing, will be 
presented for the Induction Part of the study:
!ECOG performance status at baseline (0 or 1)
!Physician assessment of peripheral neuropathy (PN) at baseline
!Assessment of diabetes in medical history, which will support subgroup analyses of 
diabetic subjects
7.2.5. Lung Cancer History
The following items will be summarized for lung cancer history:
!Disease stage before administration of Induction therapy (IIIB or IV)
!Method of specimen co llection (biopsy, s urgical specimen, FNC, other)
!Confirmation of squamous cell histology and type (papi[INVESTIGATOR_1396], clear cell, basaloid, and 
other)
!Time from latest systemic anti-cancer ther apy to first dose date in months
!Time from latest cancer therapy (last to o ccur of systemic anti-cancer therapy, 
radiation, or cancer surgery) to first dose date in months.
Subject listings will be provided for all of the above, as well as date of specimen collection.
7.2.6. Medical History
A summary of medical and surgical history will be presented by [CONTACT_625542] (SOC) and preferred term (PT). A similar summary will be generated for the currently active abnormalities only, by [CONTACT_3592].
7.2.7. Prior and Concomitant Anti-Cancer Therapy
[IP_ADDRESS]. Prior Systemic Anti-Cancer Therapy
Prior systemic therapi[INVESTIGATOR_014] (e.g. chemotherapy) w ill be summarized by [CONTACT_625543] O rganization (WHO) drug dictionary. The duration, 
whether the number of cycles is known, the number of cycles (if known), and the best response 
will be presented in a listing.
[IP_ADDRESS]. Prior and Concomitant Radiation Therapy
The number and percentage of subjects who had any prior or concomitant radiation therapy will 
be presented. For subjects with prior and concomitant radiation therapy, the number and &(/*(1r 1([ZIP_CODE],(7$5<,1)250$7,21analyses of nalyses of 
rapyapy(IIIB o(IIIB oyy
specimen, specimen, 
d tyd type (pappe (papyyy
r therapyr therapy toty
(last to occ(last to occ
o fio first doserst doseiii
all of the aball of the
surgicalsurgical  hihll
ed term (PTd term (P
only, only, by [CONTACT_625544] S
and Conand Con
Prior SystPrior Syst
yystemic thestemic the
eric drug neric drug n
whether thewhether the
will be pwill be p
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 22percentage of subjects with each treatment site of radiation therapy will be presented. Duration, 
dose, fraction (where known), intent (adjuvant, curative, palliative, unknown) and setting (stand-
alone, concurrent with other anti-cancer therapy, sequential to other anti-cancer therapy) will be 
summarized.
Prior radiation therapi[INVESTIGATOR_275408].
[IP_ADDRESS]. Prior and Concomitant Non-small Cell Lung Cancer Surgeries
The number and percentage of subjects who had any prior or concomitant non-small cell l ung 
cancer surgery will be presented by [CONTACT_6657]. Prior and 
concomitant surgeries will be listed.
7.2.8. Prior and Concomitant Medications
Medications reported on the Prior and Concomitant medications CRF pages will be coded to 
therapeutic drug classes and generic drug names using the WHO drug dictionary version WHO-DDE Q3 2013. Medications initiated prior to the start of study treatment and continued after the 
start of study treatment will be counted as both prior and concomitant medications. 
[IP_ADDRESS]. Prior Medications
Prior medications are defined as all medications that were started before Day 1 of treatment for 
the Induction Part. A summary showing the number and percentage of subjects who took prior 
medications will be presented by [CONTACT_625545]. This summary w ill be presented for the ITT population.
[IP_ADDRESS]. Concomitant Medications
Concomitant medications for the Induction Part ar e defined as any non -study medications that 
were taken on/after the date of the first dose of study drug and within [ADDRESS_833351] discontinues without being randomized, or taken on/after the date of the first dose of study drug and before the randomization date if the subject is 
randomized into the Maintenance Part.
Summaries showing the number and percentage of subjects who took concomitant medications 
will be presented by [CONTACT_625546].
7.2.9. Study Treatments and Extent of Exposure
All study treatment and extent of exposure summaries will be provided based on the safety 
population. Descriptive statis tics will be provided for treatment duration, number of cycles, 
cumulative dose, dose intensity, and percentage of protocol dose. 
[IP_ADDRESS]. Treatment and Cycle Start and End Dates
Induction tr eatment will commence on Day [ADDRESS_833352] day of any study drug.
Cycle Start and End Dates of Induction Part&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ill be codedl be code
narynary versioversi
and continund con
medicatmedicat ioio
arted beforarted befor
percentage percentage 
yyththerapeuterapeut
populatpopulat ioonn
n PartPartare dare d
dose of studose of st
ect discontect discon
drug and bdrug and 
nce Partce Part ..
umber and mber and 
HO therapeHO therap
dy Treatmdy Treat
reatment aneatment an
on. DDescriescri
latlative doseive dos
[IP_ADDRESS].[IP_ADDRESS].
ductduct
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833353] day of any Day 1 carboplatin administration 
(as recorded on the eCRF). Cycle end dates in the Induction Part are defined as the day before 
Day [ADDRESS_833354] cycle in the Induction Part, 
will be calculated as follows:
!For subjects who are not randomized, the maximum of date of last nab-paclitaxel 
dose + [ADDRESS_833355] carboplatin dose + 20 will be used as the treatment end 
date.
!For subjects who are randomized: 
oIf the last dose is Day [ADDRESS_833356] dose is Day 15 of Cycle 4, then the minimum of Day 15 plus 6 days 
and the day before randomization date will be used for the treatment end date 
for the Induction Part.
In the event that the last dose is administered on the same day as 
randomization, then the treatment end date w ill be the randomization 
date.
The cycle number for each date of interest, e.g., AE start date, will be calculated based on the 
cycle window set by [CONTACT_625547]. 
[IP_ADDRESS]. Dosing Period for Each Study Drug
Dosing periods will be defined for each study drug and will be used as the denominators for the 
calculation of dose intensity for each drug. 
Conceptually, the dosing period for a study drug is the time period starting at the first dose of the 
study drug and ending a protocol- and subject-specific number of days after the last dose, depending on the dosing schedule for the treatment arm and the subjectâ€™s status. Ending the 
dosing period on the date of last dose would lead to  an overestimation of the dose intensity. To 
avoid such overestimation, additional days of dosing period beyond the date of the last dose allow for the calculated dose intensity to reflect the degree to which the subjectâ€™s dosing 
schedule aligned with the protocol-specified dose intensity. A subjectâ€™s dosing period never 
extends beyond the date of death, but it can extend beyond the treatment discontinuation date in 
some circumstances.
For subjects who participate in the Maintenance Part, nab-paclitaxel dosing periods in the 
Induction Part are equal to tr eatment duration for the Induction Part. See Sections [IP_ADDRESS] and 
[IP_ADDRESS]. For subjects who participate in the Main tenance Part, carboplatin dosing period is the &(/*(1([ZIP_CODE],(7$5<,1)250$7,[ADDRESS_833357] imim
or the calcor the calc
edule alignedule align
extends beyxtends bey
some ciome c ri
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 24minimum of the study day of the Cycle 4 Day 1 dose of carboplatin plus 20 and the day number 
of the day before randomization.
For subjects who are still on treatment in the Induction Part at the time of clinical cutoff and 
subjects who discontinue during the Induction Part prior to the clinical cutoff date, the specific calculations of the Induction Part dosing period for each study drug and arm are given in Table 2
below:
Table 2: Calculation of Induction Dosing Period for Each Study Drug Based on Cycle 
Day Number of Last Dose of the Study Drug
(For subjects who are still on treatment in the Induction Part at the time of clinical cutoff and 
subjects who discontinue during the Induction Part prior to the clinical cutoff date)
nab-Paclitaxel Carboplatin
Last dose record is D1, D8, or D15 Last dose record is D1
min{study day of death date (if it exists), study day of 
date of last dose of nab-paclitaxel + 6}min{study day of death date (if it 
exists), study day of date of last dose of carbopl atin +20}
where the last dose is the latest exposure record of the respective treatment regardless of the 
actual dose or whether the dose was administered.
[IP_ADDRESS]. Treatment Duration
Treatment duration (in weeks) is defined as: 
[(Treatment end date for the Induction Part) â€“ (Day 1 of treatment for the Induction Part) + 
1]/7. 
Cycle duration is defined as the time period from Day 1 of each cycle to the day prior to Day 1 
of subsequent cycle; for the last Induction cycle, the end date is the treatment end date for the 
Induction Part as defined in Section [IP_ADDRESS] .
Descriptive statistics will be provided for treatment duration and total number of cycles for both 
carboplatin and nab-paclitaxel. Number of subjects will also be tabulated by [CONTACT_625548]-paclitaxel.
[IP_ADDRESS]. Cumulative Dose 
Cumulative dose is defined as the sum of the values entered on the dose assigned field on the 
exposure eCRF, taken across the Induction Part in mg/m2for nab-paclitaxel or mg*min/mL for 
carboplatin. Cumulative dose will be computed separately for nab-paclitaxel and carboplatin. 
Only doses that were actually administered will be included in the cumulative dose. Descriptive 
statistics will be presented for cu mulative dose for the safety population. &(/*(1([ZIP_CODE],(7$5<,1)250$7,21and and
[ADDRESS_833358] is D12525
dydy daydayyy ofofyyddff
)), study, study  da dyy
seeofof carbo carboff1)
pective treapective trea5<
7$
n Partn Part ) ) â€“(
ime period ime period
st InductionInductio
SectSectioinn77
will be proviill be prov
paclitaxelpaclitaxel
or both carbr both carb
CumulativCumulativ
ttive dose isdose i
sure sure eCRFeCRF
arboplarbopl atainin
Only doseOnly dose
atistatistii
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary [IP_ADDRESS]. Dose Intensity
Dose intensity for a study drug is defined as th e cumulative dose divided by [CONTACT_625549]. Dose intensi ty will be calculated separately for nab-paclitaxel and
carboplatin.
Dose intensities will be calculated as follows:
!Dose intensity for carboplatin (mg*min/mL/w k) = [cumulative dose for carboplatin in 
mg*min/mL]/[carboplatin dosing period in weeks];
!Dose intensity for nab-paclitaxel (mg/m2/wk) = [cumulative dose for nab-paclitaxel in 
mg/m2]/[ nab-paclitaxel dosing period in weeks].
Dose intensity will be presented by [CONTACT_9934] f or the Induction Part of the study for the safety
population.
[IP_ADDRESS]. Exposure, Dose Reduction/Delay, and Doses Not Administered7.[IP_ADDRESS]. Dose Reduction 
A dose reduction is defined as a dose administer ed after the Cycle [ADDRESS_833359] received at the previous dosing visit.   
[IP_ADDRESS].2. Dose Not Administered
A dose not administered is any scheduled dose that is not administrated.
[IP_ADDRESS].3. Dose Delay
A dose is considered delayed if the dose was administered later than the expected date prescribed 
by [CONTACT_625550], given the consideration that an administrative window of 
Â± 2 days is permitted for all visits except C1D1.    
Subjects are to be dosed with either nab-paclitaxel on Day 1, 8, and 15 and with carboplatin on 
D1 in each of the 4 cycles in the Induction Part.  
[IP_ADDRESS].3.1. Definitions of actual dose date, reference date, and expected dose date
Assuming all the dose and visit dates are available and entered in the database as described in the 
CRF completion guidelines, then the definitions below provide the precise method for the 
determination of a dose delay. If any of the dates required for the determination of a dose delay is missing, then the imputation rules in the ne xt section (Secti on [IP_ADDRESS].3.2) will be applied to 
facilitate the calculations. 
The actual dose date is defined as the date when at least one of the IPs was administered, or 
when all the planned IPs were not administered as entered by [CONTACT_625551].  
!If more than one IP was to be administered at a dose visit, but the IPs were given at 
different dates, then the latest dose dates among the IPs will be taken as the actual dose &(/*(1([ZIP_CODE],(7$5<,1)250$7,21in n 
afetafetyy
eded
 [ADDRESS_833360] ioi
of actual of actua
ose and vis and vis
n guin gui delinesdeline
n of a dose n of a dose 
, then the imthen the im
e the calcue the calcu
he he actual dactual d
when all when all tt
nd thend the
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833361] of the dose dates will be taken as the actual dose date for that visit.
!For the calculation of dose delay parameters, if none of the planned IPs was administered 
at a dose visit, then that dose visit will be considered for â€œdose not administeredâ€ calculations only, but not for â€œdose delayâ€ calculations.  
The reference date is defined as the previous visit at which the patient was to be dosed with any 
of the IPs. For example, the reference date for Day 8 is D1.    
The expected dose date for the current visit is defined as 7+2 days after the reference date for 
nab-paclitaxel and carboplatin.     
A dose delay is declared if the actual dose visit date is later than the expected dose visit date. 
[IP_ADDRESS].3.2. Imputation Rules for the Reference DateFor the determination of the actual dose date, the current dose date of the visit of concern 
should be utilized.  If the dose date is not available, then the dose is considered â€œnot administeredâ€.  No further consideration should be given regarding dose delay for that visit. 
For the determination of the reference date, use the previous dose date if available, or the 
previous visit date if the previous dose date is missing.  If both are missing, then use the dose date from two visits prior to the current dose visit, or the corresponding visit date if the former is 
missing.  If both are missing, then use the dose date from three visits prior to the current dose 
visit, or the corresponding visit date if the dose date is missing. This logic can be extended accordingly until a dose date or visit date can be identified for the calculation of the reference 
date for the current dose visit of concern.  
It should be noted that there are two scenarios for which the dose date could be missing:  
1.The patient was physically present at the clinic and some measurements were taken, but 
the IPs were not administered as prescribed by [CONTACT_760], then the dose date in the Exposure database will be missing while the visit date would have been entered and is available in the Visit module database. 
2.If the patient was not physical present at the clinic, then both the dose date in the 
Exposure database and the visit date in th e Visit module databas e will be missing.
Each dosing record of the IPs will be listed. If any overdose occurred and reported on the 
Investigational Drug Overdose CRF page, then it will be summarized (e.g., number of subjects with overdose on each IP, difference in  planned duration of infusion and actual duration of 
infusion, difference in planne d dose and actual dose, whether the overdose result in any adverse 
event), and will also be  displayed in a listing. &(/*(1([ZIP_CODE],(7$5<,1)250$7,21fofor 
ose se visit visit dd
the visit ofthe visit o
consideredonsidered
ng dose dedose de
us dose dats dose dat
If both are both ar
the correspthe corresp
e froe fro m mththreh
date is misdate is mi
be identbe ident ifif
scenarios fscenario
lylypresent apresent 
inistered asinistered a
e will be mwill be m
Visit modVisit mod
ient was noient was no
sure ure databadatab
dosing recodosing reco
estestigatigatioionana
wiwiththiii overdoverdhh
infusionfusio n
nt
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 27Treatment exposure and dose reductions, delays, and doses not administered will be summarized 
as follows:
!Number of cycles and doses administered;
!Number and percentage of subjects with at least 1 dose reduction, number of dose 
reductions, and reasons (adverse event or other) for reduction, by [CONTACT_89835];
!Number and percentage of subjects with at least one dose delay, number of dose 
delays, by [CONTACT_89835].
!Number and percentage of subjects with at least 1 dose not administered, number of 
doses not administered, and reasons (adverse event or other) for dose not administered, by [CONTACT_89835]. If the reason for dose not administered is not given, it will be categorized as â€œData Not Availableâ€ in summary tables.
[IP_ADDRESS]. Percentage of Protocol Dose
Percentage of protocol dose is the dose intensity divided by [CONTACT_625552], expressed 
as a percentage.
!Percentage of protocol dose = (dose intensity / protocol weekly dose) * 100%
The protocol weekly doses are as follows:
!nab-Paclitaxel: 100 mg/m
2/wk (total of 12 doses â€“ 1 each for days 1, 8, and 15 for 
each cycle * 4 cycles / 12 weeks in duration)
!Carboplatin: 2 mg*min/mL/wk (6 mg*min/mL * total of 4 doses â€“ 1 on day 1 of each 
of 4 cycles / 12 weeks in duration)
Percentage of protocol dose for carboplatin and nab-paclitaxel will be categorized into <20%,
â‰¥20% to < 30%, â‰¥30% to < 40%, â‰¥40% to < 50%, â‰¥50% to < 60%, â‰¥60% to < 70%, â‰¥70% to < 
80%, and â‰¥80 to <90% and â‰¥90%, and frequency counts will be provided for the safety 
population.
7.2.10. Efficacy Analysis
All efficacy evaluations will be conducted using the ITT population. Any presentation of 
response for the Induction Part of the study w ill be for descriptive or estimation purposes only. 
The percent change from nadir during the Induction Part in sum of total length is required to 
assess target lesions for tumor progre ssion. This is calculated as follows:
Percent change from nadir at a given visit= (total  length â€“ nadir in total length) / (nadir in total 
length) x 100%, where nadir is calculated using all measurements before the visit in question, including baseline.
Listings will be provided for all endpoints. To support RECIST 1.1 assessments, the following 
information will be presented in listings:
!Per subject visit:&(/*(1([ZIP_CODE],(7$5<,1)250$7,21er of er of 
d is not d is not 
es.
ocolcolweeklyweekl
otocolotoco weekwee
2 doses 2 doses â€“â€“1
ration)ration
mmg*min/mg*min/mmm
on)on)
platplatin and in an
40% to < 50% to < 
%%, and freq, and freq
alysisalys
ons will bens will b
nduction Pnduction P
change fromchange from
get lesit lesi ons ons 
nt change fnt change 
ngth) x 100th) x 100
inncluding bcluding b
ststinging
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 28oDate of assessment
oNumber of target lesions
oTotal length of target lesions
oPercent change from nadir of sum of total length (derived as above to review 
assessment of progressive disease)
oPercent change from baseline of sum of total length to review assessment of 
response
oAssessment of target lesions
oAssessment of non-target lesions
oPresence of symptomatic deterioration
oOverall tumor response assessment
oBest overall response
!Per lesion at each subject visit:
oLocation
oMethod of assessment
oTumor length (target lesions only)
!Overall per subject
oThe best response over the Induction Part
[IP_ADDRESS]. Tumor Response and Overall Response Rate
The primary purpose of the Induction Part is to id entify subjects who achieve a radiologically 
assessed tumor response of SD, PR, or CR without clinical progression according to RECIST 1.1 
criteria at the end of Cycle 4 and are therefore eligible for randomization into the Maintenance 
Part of the study.
The number and percentage of those with a tumor response of SD, PR, or CR will be presented, 
as well as the number and percentage with each of PD, SD, PR, CR, and unevaluable (UE). The 
denominator for the percentage will include all Induction Part ITT subjects, regardless of whether they had a tumor assessment. Subjects with no tumor assessments will be considered 
UE. This analysis will be presented for each protocol-specified CT scan (Week 6 for the end of 
Cycle 2, and Week 12 for the end of Cycle 4). If there is more than one CT scan within a relative day range, the best response will be counted. Relative study day windows are presented in 
Section 11.4.
The overall response rate is the percentage of subjects who achieved best response of confirmed
PR or CR compared with baseline, where baseline is the last CT-scan obtained prior to or on Day 
[ADDRESS_833362] response of PR or CR has to be 
confirmed by [CONTACT_625553] 28 days after the response criteria are met. The ORR along with 95% Clopper-Pearson confidence interval will be presented. The following 
rules will be observed for response rate in the Induction Part:&(/*(1([ZIP_CODE],(7$5<,1)250$7,21duction Paduction P
RResponseesponse
Partartis to idis to id
, or CR witor CR wi
d are therefod are theref
ge of thosege of th
and percenand percen
e percentagercentag
a tuma tum or aor a
ysis will besis will b
nd Week 12d Week 12
ge, the bestge, the bes
onon11.411.4..
he overallhe overall
PR or CRPR or CR
of trft
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 29!For subjects who participate in the Maintenance Part, use best response among any 
tumor assessments on or before the day of randomization.  The first radiographical evaluation performed within 91 days after randomization can be utilized as the 
confirmation scan, if necessary.
!For subjects discontinued prior to the Maintenance Part, use best response on or up 
until the patient receives a subsequent anti-cancer therapy
!All Induction Part ITT subjects will be included for this analysis.
!Confirmation of CR/PR will be programmed according to the standard guidance 
document created by [CONTACT_625554].
[IP_ADDRESS]. Disease Control Rate
Disease Control rate is defined as the percent of subjects who have a radiologic complete 
response, partial response, or stable disease according to RECIST 1.1 guidelines, as determined 
by [CONTACT_093]. Disease Control rate over the Induction Part al ong with associated Clopper-
Pearson 95% CI will be presented for the Induction ITT population.
[IP_ADDRESS]. Time to Response
Time to response is defined as the time from the first dose of study drug to the first occurrence of 
confirmed response (CR or PR). Time to response will be summarized with descriptive statistics.
Only subjects with a CR or PR as a best over all confirmed response during Induction will be 
included in this analysis.
7.2.11. Safety Analyses
The purpose of this section is to describe the safety analyses for the Induction Part of the study. 
Adverse events and laboratories will be  analyzed based on th e safety population.
[IP_ADDRESS]. Adverse events
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA)
Version 17.0 or above. Appendix 11.5 gives the dates of application of new versions of 
MedDRA.
Adverse events will be analyzed in terms of treatment emergent adverse events (TEAEs), defined 
as any AEs that began or worsened in grade on or after Day 1 of treatment for the Induction Part
and on or before the date of rando mization for those who enter in the Maintenance Part, or 
through treatment discontinuation date plus 28 days for those who do not enter in the 
Maintenance Part. In addition, any SAE deemed by [CONTACT_625555] 
a TEAE, even if beyond the 28-day window.
For the summary of treatment related AEs, a treatment-related TEAE is defined as an adverse 
event which was considered to be related, reported as â€œsuspectedâ€ in eCRF, to either component 
of combination drugs. Additionall y, for related AEs reported as â€œsuspectedâ€ in eCRF to each 
individual drug, nab-paclitaxel or Carboplatin will be summarized for each study drug. If a 
subject experiences multiple occ urrences of the same AE with different relationship to study 
medication categories, the subject w ill be c ounted once, as a relationship category of treatment &(/*(1([ZIP_CODE],(7$5<,1)250$7,21cocompmplete let
ines, as detines, as d
hh associassocih ate
studystud  drugdruy
summarizesummariz
mmed eresponrespo
the safetthe safet y ay
e analyzed analyzed
d using the d using the 
ppendix endix 11.1
l be analyzl be analyz
began or wbegan or w
ore eththe date dat
eatmatment disent dis
nance Partnance Part
EAE, even iEAE, even 
For the sumFor the sum
event whvent w
com
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 30related. AEs with a missing relationship will be pre sented in the summary table as a relationship 
category of â€œtreatment-relatedâ€.
The incidence of TEAEs/treatment related TEAEs w ill be summarized by [CONTACT_57807] (SOC) and preferred term (PT) in a decreasing frequency order for SOC or PT. If a subject experiences multiple AEs under the same preferred term (system organ class), then the 
subject will be counted only once for that preferre d term (system organ class). The intensity of 
AEs will be graded 1 to 5 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. For all other AEs not described in the 
CTCAE criteria, the intensity will be assessed by [CONTACT_27414] (grade 1), moderate 
(grade 2), severe (grade 3), life-threatening (grade 4) or death (grade 5). If a subject experiences the same AE more than once with different toxicity grade, then the event with the highest grade 
will be tabulated in â€œby [CONTACT_479]â€ tables. In addition, AEs with a missing intensity will be presented 
in the summary table as an intensity category of â€œMissing.â€
Tables summarizing the incidence of TEAEs will be generated for each of the following:
!Overall summary of TEAEs;
!TEAEs presented by [CONTACT_11189], preferred term, and worst CTCAE 
grade
!Treatment-related TEAEs by [CONTACT_625556] (grade 1-2 vs. grade 3-4 vs. grade 5; 
overall and by [CONTACT_5265]);
!Serious TEAE by [CONTACT_625557];
!Treatment-related serious TEAE by [CONTACT_625557];
!TEAEs with action of study drug withdrawn;
!Treatment-related TEAEs with action of study drug withdrawn;
!TEAEs with action of study drug dose reduced or interrupted;
!Treatment-related TEAEs with action of st udy drug dose reduced or interrupted;
!TEAEs with fatal outcome;
!Treatment-related TEAEs with fatal outcome;
!All deaths within 28 days of treatment di scontinuation date with cause of death;
!Most frequent TEAEs ( â‰¥5%; sorted by [CONTACT_9560], without SOC);
!TEAEs for the following baseline subgroups (provided the number of subjects are 
sufficient):
#Age (<65 years versus 65 to â‰¤ 74 years versus â‰¥ 75 years)
#Sex (male versus female)
For TEAEs that are summarized by [CONTACT_5265], the following rules will be used:
!TEAEs which occur on Day 1 Cycle 1 belong to Cycle 1.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21te e 
riences iences 
hest est grade grade 
l be presenl be presen
he fohe fo llollwinwi
erred termerred term
de 1de 1--[ADDRESS_833363] freque
TEAEs fTEAEs f
sufficiuffici
##
T
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 31!After cycle 1, TEAEs will be categorized by [CONTACT_941] â€œthrow-back ruleâ€, that is, TEAEs 
that occur on Day 1 of a cycle will be allocated to the previous cycle.
!All TEAEs which occur after Day [ADDRESS_833364] cycle.
For subjects who are randomized, all TEAEs which occur after Day 1 of Cycle 4 and
on or before the randomization date will be included in Cycle 4.
Data listings will be presented for all TEAEs. A listing for non-treatment-emergent AEs will also 
be provided. 
[IP_ADDRESS]. Peripheral Neuropathy
Peripheral neuropathy events will be collected on the Physician Assessment of Peripheral 
Neuropathy eCRF and reported as AEs and will be included in analyses described in 
Section [IP_ADDRESS] . A summary of PN grade by [CONTACT_625558].
For subjects who were treated in the Induction  Part only (i.e., subjects who discontinued 
treatment without being randomized), additional summaries of peripheral neuropathy events will be presented using both the AE data and the PN eCRF data. Adverse events will be considered 
PN events if they are TEAEs and are iden tified as peripheral neuropathy based on the 
Standardized MedDRA Queries (SMQs). The following will be summarized:
!Number and percentage of subjects who develop grade 3 or higher peripheral 
neuropathy;
!Time to first onset of grade 3 or higher peripheral neuropathy;
!Time to improvement of grade [ADDRESS_833365] 1 grade; 
and
!Time to improvement of grade [ADDRESS_833366] onset will be summarized with 
descriptive statistics for only those subjects who experienced peripheral neuropathy of the relevant grade. There will be no censoring. 
Time to improvement of the grade â‰¥[ADDRESS_833367] a grade â‰¥[ADDRESS_833368] is evaluated for adverse events. 
[IP_ADDRESS]. Adverse Events of Special Interest
The following summaries will be provided for TEAEs included in the above-mentioned AEs of 
interest: 
1. TEAEs by [CONTACT_372153]; 2. Serious TEAEs; 
3. TEAEs with action of drug withdrawn;&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ral ral 
n 
ased on the ased on the 
o dio discontscont ini
ral neuroparal neurop
e events wievents wi
ropathypa bby[CONTACT_625559] 3 op grade 3 
peripheral peripheral 
r hir higher pergher per
ade 3 or higde 3 or hi
nts expectents expecte
those subjethose subj
be no cense no cens
of the gradof the gr
â‰¥3 PN evenâ‰¥[ADDRESS_833369]: erest: 
1.1.
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 324. TEAEs with action of dose reduced or interrupted;
5. TEAEs with fatal outcome;
TEAEs of special interest will be listed.
[IP_ADDRESS]. Clinical Laboratory Evaluations
Listings will be provided for the local laboratory data. 
[IP_ADDRESS].1. Hematology
All hematology data will be listed. 
[IP_ADDRESS].2. Clinical Chemistry
All clinical chemistry data will be listed.
[IP_ADDRESS]. Concurrent Radiation and Surgeries
The number of subjects having concomitant radiat ion or surgeries and procedures performed will 
be summarized.
Concomitant radiation or surgeries will be listed.
7.2.12. Quality of Life Analysis
The Lung Cancer Symptom Scale (Pol) and EQ-5 D-5L questionnaires will be used to measure 
quality of life (Q oL) for subjects in the trial. The LCSS is a [ADDRESS_833370] 
completes using a visual analogue scale (VAS) to denote intensity of a symptom. The EQ-5D-5L
comprises 5 questions on mobility, self-care, usu al activities, pain/discomfort, anxiety/depression 
and a VAS for overall QoL. In addition, there is an overall index score that is derived from the 5 
questions. These questionnaires will be comp leted at Day 1 of every cycle, and at Early 
Treatment Discontinuation/End of Cycle 4 during the Induction Part of the study. Baseline scores 
are defined as scores captured on Day 1 (first dose date). In the case of multiple assessments on 
Day 1, the later assessment will be used. Missing baseline scores will not be imputed.
For administrative purposes (e.g., planning of ne w studies, publication of data) the LCSS and 
EQ-5D measurements collected during the Induction Part will be summarized overall and by 
[CONTACT_625560] s tatistics as needed when  approximately 50, 100, 200, 400, and all 
subjects, respectively, have either discontinued during or completed the Induction Part of the 
study. Subgroups may include but are not limited to  radiological response and baseline symptom 
status.
[IP_ADDRESS]. LCSS
The LCSS is designed to measure quality of li fe specifically affected by [CONTACT_625561]. It evaluates burden due to six major symptoms:
!Appetite
!Fatigue
!Coughing&(/*(1([ZIP_CODE],(7$5<,1)250$7,21d procedureprocedure
LLquestionquestion
LCSS is a 9LCSS is a 9
to denote io denote
usual activusual activ
here is an ohere is an o
cocompmpletedte
Cycle 4 durycle 4 du
n DayDay 1 (fir1 (firyy
ill be used. ll be used
ses ((e.g.e.g, p
cocolllected lected 
cririptptiiiive ivestast
ively, ively, havehave
ups ps mamay y ini
.1..1. LCSSCSS
he LCSS ishe LCSS is
symptomymptom
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 33!Shortness of breath
!Blood in sputum
!Pain
In addition, it measures how bad a subjectâ€™s sy mptoms are, how much lung cancer has affected 
normal activities, and global quality of life. 
The LCSS consists of two scales: one to be filled  out by [CONTACT_625562]. For this  study, only the portion filled out by [CONTACT_625563]. The subject will 
respond to each of the 9 items using marks on a 100 mm visual analog scale (VAS). For analysis 
and presentation purposes, the scores will be presented such that [ADDRESS_833371] and will be
referred to as the LCSS total score. The symptom burden index is the average of the 6 symptom-specific items (the first 6 i tems). The averag e of the coughing, shortness of breath, and blood in 
sputum items will be referred to as the Respi[INVESTIGATOR_625528]. The average of the appetite 
and fatigue items (the first 2 items) will be referred to as the overall constitutional score. The sum of the symptoms item (item 7), the normal activities item (item 8), and the global quality of 
life item (item 9) will be referred to  as the general health scale.
Summary statistics of the individual LCSS items  and summary scale scores, the change from 
baseline, and percent change from baseline will be summarized for the ITT population at every 
time point at which the instrument is given, and at end of Induction (i.e., last assessment during 
Induction or Cycle [ADDRESS_833372] ). In addition, the change from baseline to the 
LCSS score during the Induction Part, defined as the difference between the last reported LCSS 
score during the Induction Part, either the end of [ADDRESS_833373] not reached that point at an interim analysis, will be presented.
[IP_ADDRESS]. EQ-5D-5L
The EQ-5D-5L has been designed as an international, standardized, generic instrument for 
describing and valuing health-related quality of life. It contains only the domains common to 
generic health status measures, contains the minimum number of questions for each domain, was 
designed for ease of self-administration, and produces a single index for analysis. 
Five dimensions are covered by [CONTACT_20367]-5D-5L:
!Mobility
!Self-care
!Usual Activities
!Pain/Discomfort
!Anxiety/Depression
The 5 dimensions are scored on a 5-point Likert s cale. In addition, there is a question covering 
perceived change in health status over the previous 12 months measured on a 20 cm vert ical &(/*(1([ZIP_CODE],(7$5<,1)250$7,21ll 
nalysis nalysis 
he worst he worst
nd will bed will be
of of the 6 sye 6 sy
f breath, andbreath, an
e average overage
constitutiononstitutio
mm 8) mm, and and t
maryaryscale scale
marized formarized fo
d of d ofInductnduct
n additn addit ioion, n, 
as the diffes the diff
nd of 4 cycld of 4 cycl
ff for subjecff for subje
igned as angned as an
alth-h-relatedrelated
easures, coeasures, co
selfelf-admin-adminff
s are coveres are cover
ilitilityy
SelfS-fcarecare
!!Usual Usual 
!PaPa
!
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 34visual analog scale â€œthermometerâ€ to summarize oneâ€™s overall health status at administration on 
a 100-point scale.
Responses from the 5 dimensions are coded so that a â€˜1â€™ indicates no problem on that dimension, 
and â€˜5â€™ indicates the most serious problem. A profile is comprised of [ADDRESS_833374] imaginable h ealth state.  
A utility score will be calculated using the US Crosswalk Index Value Set obtained from the 
EuroQol website. The range of possible values for the utility score based on the US Crosswalk Index Value Set is -0.109 to 1.000. The overall utili ty score, change from baseline, and percent 
change from baseline in the overall ut ility score w ill be summarized for every time point at 
which the instrument is given for the ITT population. 
Shifts from baseline to each time point at which the instrument is given will be presented for 
each dimension for the ITT population. 
Summaries of the VAS results and the change and percent change from baseline will be 
presented for every time point at which the instrument is given.
7.3. Maintenance Part
7.3.1. Study Population Definitions
[IP_ADDRESS]. Intent-to-Treat Population
The primary efficacy analysis will be performed on the ITT population, which includes all 
randomized sub jects regardless of whether the subject receives any study regimen or has any 
efficacy assessments collected. In all ITT analyses, subjects are analyzed according to their 
randomized treatment, regardless of what treatment they may receive at any time after 
randomization.
[IP_ADDRESS]. Response Evaluable Population
Response evaluable (RE ) population includes all randomized subjects who meet eligibility 
criteria, take at least one dose of study drug or are on BSC and have at least one baseline and one 
post-randomization efficacy assessment. The response evaluable population will be used in a 
replication of the primary and major secondary efficacy analyses to assess the effect of subjects who were randomized but not treated or assessed on the efficacy analysis.
[IP_ADDRESS]. Per-Protocol Population
The per-protocol (PP) popul ation, which will include all sub jects randomized in the Maintenance 
part who receive at least one dose of the study therapy or on BSC arm and do not have any 
known major protocol deviations and fulfill the study enrollment criteria. The PP population will 
be used in a replication of the primary and major secondary efficacy analyses to assess the effect of major protocol deviations on efficacy. Protoc ol deviations and their handling for analysis 
purposes, are discussed in more detail in Section 6.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21he 
sswalk sswalk 
nd percent nd percent 
e point at point at 
ll be presenl be presen
om m baselinbaselin
med on themed on the
er the subjeer the subje
TT analyseTT analyse
f what treatwhat trea
uable Popuable Pop
E) E) populatpopulat
one dose oone dose 
oonnefficacyefficacy
the primaryhe primar
andomizedandomized
3.3. Perer-P
he he pperer-protprot
part parwho who 
nownnown
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary [IP_ADDRESS]. Safety Population
The safety population incl udes all randomized subjects. The safety population w ill be the basis
of all safety analyses. Subjects who receive nab-paclitaxel in error will be analyzed by [CONTACT_492781].
7.3.2. Demographics
Demographics will be summarized for the ITT population. Age (years) and weight (kg) at 
baseline will be summarized descriptively. Age category (<65 versus > 65 years, <70 versus â‰¥70 
years, and < 75 versus â‰¥ 75 years), sex, race, and ethnicity will be summarized by [CONTACT_444688].
Age will be calculated as follows: age = Integer âˆ€[(Date of informed consent â€“ Date of Birth + 
1) / 365.25]. 
7.3.3. Baseline Characteristics
The following characteristics co llected before the beginning of the Induction Part will also be 
presented for the subjects in the Maintenance Pa rt of the study by [CONTACT_120387]:
!Assessment of diabetes in medical history, which will support subgroup analyses of 
diabetic subjects
In addition, the following measures collected before  the Maintenance Part of the study will be 
summarized. The last non-missing measure before rando mization be considered bas eline for 
these measures:
!ECOG performance status at end of Induction (0 or 1)
!Physician assessment of peripheral neuropathy (PN)
!The tumor response (CR, PR, and SD) achieved in the Induction Part
7.3.4. Lung Cancer History
The following items will be summarized by [CONTACT_625564]:
!Disease stage before administrati on of Induction therapy (IIIB or IV)
!The time from the first diagnosed date of lung cancer (specimen co llection date if the 
diagnosed date is unknown) to Day 1 of treatment for the Induction Part in months, 
defined as (Day 1 of treatment for the Induction Part â€“ the first diagnosed date (or 
specimen collection date if the diagnosed date is unknown) + 1)/30.4375
!Method of specimen co llection (biopsy, surgical specimen, fine needle cytology 
(FNC), other)
!Confirmation of squamous cell histology and type (papi[INVESTIGATOR_1396], clear cell, basaloid, and 
other)
Subject listings will be provided for all of the above, as well as date of specimen collection.&(/*(1([ZIP_CODE],(7$5<,1)250$7,2170 70 
y 
e of Birth +e of Birth 
nductductioion Pn
y treatmenty treatmen
hich willich will  sul
re the re th MainMain
fore randoore rando mm
end of end of IIndn
periperipheralpheraii
(CR, PR, a(CR, PR, a
Historyistory
willill b blle sume su
se stage befse stage bef
he time frotime fro
didiagnosedagnosed
defineddefined
specspe
!!
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 367.3.5. Medical History
A summary of medical and surgical history will be presented by [CONTACT_625542] (SOC) and preferred term (PT). A similar summary will be generated for the currently 
active abnormalities only at rando mization, by [CONTACT_1198].
7.3.6. Prior and Concomitant Anti-Cancer Therapy
Subject listings described in the Induction Part of this SAP will include a column for tr eatment 
group, if applicable.
[IP_ADDRESS]. Prior Systemic Anti-Cancer Therapy
The number and percentage of subjects with any prior systemic anti-cancer therapy will be 
presented by [CONTACT_532199].
[IP_ADDRESS]. Prior and Concomitant Radiation Therapy
The number and percentage of subjects who had any prior or concomitant radiation therapy will 
be presented by [CONTACT_532199]. For subjects with prior and concomitant 
radiation therapy, the number and percen tage of subjects with each site of rad iation therapy will 
be presented.
[IP_ADDRESS]. Prior and Concomitant Non-small Cell Lung Cancer Surgeries
The number and percentage of subjects with any prior or concomitant cancer surgery will be 
presented by [CONTACT_1570], sys tem organ class and preferred term for the ITT population. The 
time from the last prior non-small cell lung cancer surgery to date of first dose will be 
summarized.
7.3.7. Prior Medications
Prior medications are defined as in the Induction Part. A summary showing the number and 
percentage of subjects randomized to the Maintenance Part who took prior medications will be 
presented by [CONTACT_625545]. This summary 
will be presented for the ITT population.
7.3.8. Concomitant Medications
Concomitant medications for the Maintenance Pa rt are defined as non -study medications that 
were taken on/before the rando mization and within 28 days of the tr eatment discontinuation date. 
Summaries showing the number and percentage of subjects who took concomitant medications 
by [CONTACT_625565].
7.3.9. Concurrent Radiation and Surgeries
The number of subjects having concomitant surgeries and procedures performed will be 
summarized.
Concomitant surgeries will be listed.&(/*(s*(1([ZIP_CODE],(7$5<,1)250$7,21willwill bblle e 
ntradiatradia ion
witwith prih prioror
h siste ofofi  rad raff
g gCancer SCancer S
or concomor concom
nd preferrend preferre
cer surgeryer surger
he he Inductnduct i
ed to the ed to the MM
onaryonary ththeraer
TT populatiT populat
tant Meditant Med
dicaticatioions ns fof
before the before th
showing showing 
O therapeuO therapeu
[IP_ADDRESS]. CC
The numThe nu
mm
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 377.3.10. Study Treatments and Extent of Exposure
All study treatment and extent of exposure summaries will be provided based on the safety 
population. Descriptive statis tics will be provided for treatment duration, number of cycles, 
cumulative dose, dose intensity, and percentage of protocol dose by [CONTACT_2939]. 
[IP_ADDRESS]. Treatment and Cycle Start and End Dates
Maintenance treatment will commence on Day [ADDRESS_833375] visit date of any Day1 
Cycle 5 assessments for the BSC arm.    
Cycle Start and End Dates of Maintenance Part
For subjects randomized to nab-paclitaxel + BSC, Day [ADDRESS_833376] cycle.
Cycle duration is defined as the time period from Day 1 of each cycle to one day prior to the Day 
1 of subsequent cycle (see details in Section 5.2.2).
Treatment End Date of Maintenance Part
Treatment end date for the Maintenance Part, is defined as the date before the next planned 
cycle.
The cycle number for each date of interest, e.g., AE start date, will be calculated based on the 
cycle window set by [CONTACT_625566].
[IP_ADDRESS]. Dosing Period for nab-Paclitaxel
The Maintenance Part dosing period will be defined for nab-paclitaxel and will be used as the 
denominator for the calculation of dose intensity. 
Conceptually, the dosing period for a study drug is the time period starting at the first dose of a 
study drug and ending at subject -specific number of days after the last dose, depending on the 
dosing schedule for the treatment arm and the subjectâ€™s status. Ending the dosing period on the date of last dose would lead to an overestimation of the dose intensity as the exposure to the 
study drug extends beyond the dosing date. To avoid such overest imation, additional days of 
dosing period beyond the date of the last dose allow for the calculated dose intensity to reflect the degree to which the subjectâ€™s dosing schedule aligned with the protocol-specified dose 
intensity. A subjectâ€™s dosing period for a study  drug never ex tends beyond the date of death, but 
it can extend beyond the treatment discontinuation date in some circumstances. The specific calculations of the Maintenance Part dosing period are given in Table 4below:
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21--
Day1 y1 
s s ththeedate wdate w
cle beycle b onondd
andondomizedmized
ycle [ADDRESS_833377], e.g.e.g.,,AEA
nd dates.nd dates
abab-PaclitaPaclita
ng period g period w
ulatulaionnofodf
osing perioding perio
nding anding a t t subsub
le for the tre for the 
dose wouldose woul dd
ug extends extends
g period beg period be
e degree to degree to 
intntensiensitytyii. A.A
tcan excan e
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 38Table 4: Calculation of Maintenance nab-Paclitaxel Dosing Period Based on Cycle 
Day of Last Dose
Last dose record is D1 Last dose record is D8
min{study day of death date (if it exists), study 
day of date of last dose of nab-paclitaxel + 9.5}min{study day of death date (if it exists), 
study day of date of last dose of nab-
paclitaxel + 13}
where the last dose is the latest exposure record of nab-paclitaxel regardless of the actual dose or 
whether the dose was administered.
[IP_ADDRESS]. Treatment Duration
Treatment start date for the Maintenance Part is defined as the date when the Day [ADDRESS_833378] to follow up, protocol violation, or other reason, although no study regimen was administered.
Treatment duration (in weeks) is defined as: 
[(Treatment end date for the Maintenance Part) â€“ (Treatment start date for the Maintenance Part) 
+ 1]/7.    
Descriptive statistics will be provided for treatment duration and total number of cycles for the 
nab-paclitaxel+BSC arm, both for the Maintenance Part and for the entire study. Number of 
subjects will also be tabulated by [CONTACT_625567].
[IP_ADDRESS]. Cumulative Dose
Cumulative dose is defined as the sum of the values entered on the dose assigned field on the 
exposure eCRF, taken across the study period in mg/m
2for nab-paclitaxel. Only doses that were 
actually administered will be included in the sum. 
As subjects who entered the Maintenance Part might have a different dose intensity profile than 
subjects who did not, descriptive statistics will be presented for cumulative dose over the 
Induction Part (by [CONTACT_625568]) and Maintenance Part for the nab-
paclitaxel+BSC arm for the safety population (subjects treated) in the Maintenance Part. In 
addition, cumulative dos e for carboplatin from the Induction Part, calculated as described in 
Section [IP_ADDRESS] , will be summarized by [CONTACT_625569]. 
[IP_ADDRESS]. Dose Intensity
Dose intensity of nab-paclitaxel during the Maintenance Part or entire study is defined as the 
cumulative dose divided by [CONTACT_625570], 
respectively.  Dose intensity of carboplatin will be calculated for the Induction Part only.  &(/*(1([ZIP_CODE],(7$5<,1)250$7,21$7ose or se or $7$7
50$[ADDRESS_833379]
tudy regimtudy reg
atment staratment sta
ment duratient durat
enance Parenance Pa
umber of cymber of cy
s the sum os the sum o
oss the s the stu
will be incluwill be incl
ntered the ntered the MM
d not, dd not, d esc
rtt(by(by[CONTACT_625571]
+BSCBSC armarm
n, cumn, cum ulatulatmmm
iionon7.[IP_ADDRESS].9.4
opulopulatatioion n i
3.1031 0
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 39Dose intensities will be calculated as follows:
!Dose intensity for nab-paclitaxel = [cumulative dose for nab-paclitaxel in mg/m2]/[dosing 
period in weeks].
Dose intensity for nab-paclitaxel will be presented for the safety subjects in nab-paclitaxel+BSC.
In addition, dose intensity from the Induction Part, described in Section [IP_ADDRESS] , will be 
summarized by [CONTACT_625572].
[IP_ADDRESS]. Exposure, Dose Reduction/ Delay, and Doses Not Administered
[IP_ADDRESS].1. Dose Reduction 
A dose reduction is defined as a dose administer ed after the Cycle [ADDRESS_833380] actually received at the previous dosing visit for the 
nab-paclitaxel + BSC arm.   
[IP_ADDRESS].2. Dose Not Administered
A dose not administered is any scheduled dose that is not administrated. 
[IP_ADDRESS].3. Dose Delay
A dose is considered delayed if the dose was administered later than the expected date prescribed 
by [CONTACT_625550], given the consideration that an administrative window of 
Â± 2 days is permitted for all visits except C5D1.    
Subjects are to be dosed with nab-paclitaxel on Day 1 and 8 in the Maintenance Part.
[IP_ADDRESS].3.1.Definitions of actual dose date, reference date, and expected dose dateAssuming all the dose and visit dates are available and entered in the database as described in the 
CRF completion guidelines, then the definitions below provide the precise method for the 
determination of a dose delay. If any of the dates required for the determination of a dose delay 
is missing, then the imputation rules  in the next section (Section [IP_ADDRESS].3.2) w ill be applied to 
facilitate the calculations. 
The actual dose date is defined as the date when nab-paclitaxel was administered, or when the 
planned dose was not administered as entered by [CONTACT_625573].  
!If nab-paclitaxel is given more than one time for a visit, then the latest of the dose dates 
will be taken as the actual dose date for that visit.
!For the calculation of dose delay parameters, if nab-paclitaxel was not administered at a 
dose visit, then that dose visit will be c onsidered for â€œdose not administeredâ€ calculations 
only, but not for â€œdose delayâ€ calculations.  
The reference date is defined as the previous visit at whic h the patient was to be dosed with 
nab-paclitaxel. For example, the reference date for Day 8 is D1 and the reference date for Day 1 of a cycle is D8 of the previous cycle.   &(/*(1([ZIP_CODE],(7$5<,1)250$7,21ch is at a ch is at a 
g visivisit ft fiior thor thfff
ed. ed. 
ater than thater than th
eration thatration th
ayay11yyandand88
ee, referenc, referenc
are available availabl
e definitdefinit ioio
any of the any of the
n rulrules in thes in t
is defined is define
not adminisnot admini
nabab-paclipacli tataiii
will be takwill be tak
!!For thFor t
dodo
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 40The expected dose date for the current visit is defined as  7+2 days after Day 1 and 14+ 2 days 
after Day 8.       
A dose delay is declared if the actual dose visit date is > the expected dose visit date. 
[IP_ADDRESS].3.2.Imputation Rules for the Reference Date
For the determination of the actual dose date, the dose date of the visit of concern should be 
utilized.  If the dose date is not available, then the dose is considered â€œnot administeredâ€.  No 
further consideration should be given regarding dose delay for that visit. 
For the determination of the reference date, use the previous dose date if available, or the 
previous visit date if the previous dose date is missing.  If both are missing, then use the dose 
date from two visits prior to the current dose visit, or the corresponding visit date if the dose dateis missing.  If both are missing, then use the dose date from three visits prior to the current dose 
visit, or the corresponding visit date if the dose date is missing. This logic can be extended 
accordingly until a dose date or visit date can be identified for the calculation of the reference date for the current dose visit of concern.  
It should be noted that there are two scenarios for which the dose date could be missing:  
1.The patient was physically present at the clinic and some measurements were taken, but 
nab-paclitaxel was not administered as prescribed by [CONTACT_760], then the dose date in the Exposure database will be missing while the visit date would have been entered and is available in the Visit module database. 
2.If the patient was not physical present at the clinic, then both the dose date in the 
Exposure database and the visit date in the Visit module database will be missing.
Each dosing record of nab-paclitaxel will be listed. If any overdose occurred and reported on the 
Investigational Drug Overdose CRF page, then it will be summarized (e.g., number of subjects with overdose on nab-paclitaxel, difference in planned duration and actual  duration, difference in 
planned dose and actual dose, whether the overdose result in any adverse event), and will also be 
displayed in a listing.
[IP_ADDRESS]. Percentage of Protocol Dose
Percentage of protocol dose is the dose intensity divided by [CONTACT_625552], expressed 
as a percentage.
!Percentage of protocol dose = dose intensity / protocol weekly dose * 100%
For subjects who start Maintenance therapy with an assigned dose of 100 mg/m
2, the protocol 
weekly dose for nab-paclitaxel during the Maintenance Part is 66.7 mg/m2/week (the subject will 
receive two 100 mg/m2doses of nab-paclitaxel on Days 1 and 8 of the 21-day cycle).r the the 
e the dose e the dose 
e if the e if the dosdos
to the curreto the curre
can be extean be exte
latioion of thn of
se date coue date
some measome me
ed by [CONTACT_625574]
e CRF page CRF pag
taxelaxel, diffe, diff
dose, whetdose, wh
centage of centage of 
of protocolof protoco
entage.age.
PercentPercent
For subjectFor subject
weekly weekly
eiv
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 41While it is possible that a starting dose for the Maintenance Part of 75 mg/m2may be given for 
subjects who had two dose reductions during Induction, the protocol weekly dose is 66.7 
mg/m2/week for all subjects randomized to nab-paclitaxel + BSC.
Percentage of protocol dose for nab-paclitaxel will be categorized into 10% intervals, and 
frequency counts will be provided for the safety population.
Treatment exposure and dose reductions, delays, and interruptions will be summarized for the 
nab-paclitaxel+BSC arm as follows:
!Number of cycles and doses administered;
!Number and percentage of subjects with at least 1 dose reduction, number of dose 
reductions, and reasons (Per Protocol, adverse event, or other) for reduction, by [CONTACT_625575];
!Number and percentage of subjects with at least one dose delay, number of dose 
delays, by [CONTACT_89835].
!Number and percentage of subjects with at least 1 dose not administered, number of 
doses not administered, and reasons (adverse event or other) for dose not administered, by [CONTACT_89835]. If the reason for dose not administered is not given, it will be categorized as â€œData Not Availableâ€ in summary tables.
7.3.11. Efficacy Analysis
All efficacy evaluations will be conducted using the ITT population.  Supportive analysis of the 
primary and key secondary efficacy e ndpoints using the PP and RE population will be conducted 
for the final analysis. Statistical comparisons will be made between BSC and nab-
paclitaxel+BSC arms for the Maintenance Part only. Efficacy results that will be considered statist ically si gnificant after consideration of the str ategy for controlling the Type 1 error rate are 
described in Section [IP_ADDRESS] . All statistical tests will be two-sided at the significance level of Î± 
= 0.05, a nd the corresponding p-values and two-sided confidence intervals (CIs) for intended 
point estimates will be reported.
Listings will be provided for all endpoints. To support review of tumor response data, the 
following information will be presented in listings:
!Per subject visit:
oDate of assessment
oNumber of target lesions
oTotal length of target lesions
oPercent change from nadir of sum of total length (derived as in Section 
[IP_ADDRESS] to review assessment of progressive disease)
oPercent change from baseline of sum of total length to review assessment of 
response
oAssessment of target lesions
oAssessment of non-target lesions
oPresence of symptomatic deterioration&(/*(1([ZIP_CODE],(7$5<,1)250$7,21f dose ose 
on, by[INVESTIGATOR_2394], by  [CONTACT_625576] d
administeradministe
her) for doher) for do
ose not adme not ad
eâ€ in summeâ€ in sum
ITTITTpopulpopu
ing the PPng the PP
will be madll be mad
artartonlyonly.EE
n of the strn of the 
ststicicalal tests tll
lues and es and twtw
r all endpor all endp
ill be preseill be pre
ct visit:t visit
Date of aDate of a
ooNumbNum
ooToT
oo
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833381] overall response
!Per lesion at each subject visit:
oLocation
oMethod of assessment
oTumor length (target lesions only)
!Overall per subject
oThe best response over the entire study
[IP_ADDRESS]. Multiplicity
A step down procedure will be used to cont rol the family-wise Type 1 error r ate. Ov erall 
Survival will only be tested if PFS demonstrates superiority for nab-paclitaxel+BSC vs. BSC. 
Strategies to control alpha due to repeated testing are described in Section 8.2.
[IP_ADDRESS]. Analysis of Primary Efficacy Endpoint
The primary efficacy endpoint of PFS will be analyzed using the p-value from the stratified log-
rank test of PFS based on the ITT population and will be considered the primary analysis, with the un-stratified analysis considered a supporti ng analysis.  The method for determining the 
strata is detailed below.
Progressive disease is measured using the percen t change from nadir over all tumor assessments 
in sum of total length. This is calculated as follows:
Percent change from nadir at a given visit= (total  length â€“ nadir in total length) / (nadir in total 
length) x 100%, where nadir is calculated using all measurements before the visit in question, including baseline, Induction, and Maintenance scans.
Progression-free survival will be based on investigator assessment according to RECIST 1.1 
criteria. PFS is defined as the time in mont hs from the date of rando mization to the date of 
disease progression (documented by [CONTACT_4654]-scan result,  not including symptomatic deterioration) or 
death (any cause) on or prior to the clinical cut off date, whichever occurs earlier. RECIST 1.1 
criteria defines disease progression as the occurrence of any of the following circumstances:
!Increase of 20% in the sum of diameters of the target tumors based on the smallest sum 
(nadir) over the study (for this study it is possible that the nadir occurs at baseline or 
during the Induction Part of the study even though those time points are before 
randomizatio n), with a 5 mm minimum increase
!Appearance of new lesions
!Unequivocal progression of non-target tumors
Therefore, the calculation of PFS is a two-step process:
!Determination of date of disease progression, which is the date of assessment 
corresponding to the first time that overall tumor response is â€œProgressive Diseaseâ€ on the Overall Response eCRF&(/*(1([ZIP_CODE],(7$5<,1)250$7,21Overall verall 
+BSCBSC vs. Bvs.
8.28.2.
p-value frovalue fro
idered the pdered th
The methoThe metho
hange from hange from
s:s:
otalotalllllength ength
using all musing all m
tenancetenance scs
sededon invon inv
me me in in momontnth
nted by[CONTACT_625577] c
progressionprogressio
20% in the% in the
ver the studver the stu
g the g the InductInduc
doomizatmizat ioio
AppearanAppearan
!UneqUneq
ThereforTherefo
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 43!Calculation of PFS as (date of disease progression, death, or censoring â€“ date of 
randomization + 1)/ 30.[ADDRESS_833382] begins a subsequent anti-cancer chemotherapy prior to documented disease progression (or death), the 
subject will be censored at the date of last assessment when the subject was documented as 
progression-free prior to the intervention. In the event that curative radio therapy or surgery at 
lesion sites occurs, the subject will be censored at the date of last assessment when the subject 
was documented as progression-free prior to the intervention. Subjects with a single missing 
radiologic assessment prior to a visit with documented disease progression (or death) will be analyzed as a PFS event at the time of the radiologic assessment that shows progression or death 
(whichever is earlier). Subjects with two or more consecutive missing radiologic assessments 
prior to an assessment with documented progression (or death) will be censored at the date of last 
assessment when the subject was documented as progression-free prior to the first of the two 
missing assessments. This is further illustrated in .below.
Table 5: Censoring Rules for PFS
Situation Analysis Date Censored or 
Event
Disease progression, and t ime 
interval between progression date 
and previous tumor assessment date 
with progression-fr ee response is 
less than or equal to 91daysEarliest of:
!Date of first tumor 
assessment showing new 
lesion
!Date of first tumor 
assessment with overall 
response of PDEvent
Disease progression, and t ime 
interval between the progression date and the previous tumor 
assessment date with progression-
free response is greater than 91days,
or time interval between the 
progression date and the 
randomizatio n date is greater than 
[ADDRESS_833383] of:
!the last progression-free 
assessment date
!randomization dateCensored
Death without any post-baseline 
radiological assessment, and time interval between death date and 
randomization date is less than or equal to 91daysDeath date Event
&(/Death wiDeath wi ththiii
rradiadiololoo
intntere
ra&(/*(1([ZIP_CODE],(7$5<,1Date ate<,<
ate of ate o firfirst
assessmenassessme
llesiesionon
!!DatDat$5$[ADDRESS_833384] baseL23232323
(/*&1)250$7,21ect ct 
sing ng 
will be will be 
ssion or deassion or de
assessmenassessme
red ed atathheedd
the first of he first of 
1)
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833385] progression-free 
assessment dateCensored
No death or disease progression and 
no subsequent anti-cancer therapy (i.e., systemic anti-cancer therapy, 
anti-cancer surgery, curative radiotherapy).Latest of 
!the last progression-free 
assessment date
!randomization dateCensored
Subsequent anti-cancer treatment 
(i.e., systemic anti-cancer therapy, 
anti-cancer surgery, curative 
radiotherapy) started prior to 
progression or deathLatest of 
!the last progression-free 
assessment date prior to 
start of anti-cancer 
treatment
!randomization dateCensored
Disease progression and the 
progression date is before the
randomization dateRandomization date Censored
Note: Progression-free response refers to a response that was neither progressive disease 
(PD) nor un-evaluable (UE). 
A superiority test will be performed for the pr imary efficacy endpoint of PFS. The corresponding 
two-sided hypotheses are: 
H0: HR( nab-paclitaxel+BSC vs. BSC only) = 1
versusH
1: HR( nab-paclitaxel+BSC vs. BSC only) â‰ 1, &(/*(1([ZIP_CODE],(7$5<,1)250$7,210$Censoredensored50
1)
progressionrogressio
sment datement dat
ndondomizatmiza io<
Latest of Latest of 
!!5,(
23
nnand the and the 
is before ts before 
n daten date3
ogressionogression --ff
nor unr un--evaleval(1
/*perioritperiorit y y test
o-sided sided hyhy
H00: H: H
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 45where HR( nab-paclitaxel+BSC vs. BSC only) is the hazard ratio between two treatment arms 
in the Maintenance Part of the study.
The final analysis for PFS will be conducted when a total of approximately [ADDRESS_833386] occurred on or prior to the clinical 
cutoff date will be included. The survival distribution of PFS w ill be estimated  using the Kaplan-
Meier method. The median PFS, including the two-sided 95% confidence interval (CI) for each 
treatment arm, will be provided. The survival distributions for the two treatment arms will be compared using the stratified log-rank test, and the p-value will be provided ( Klein, 2003). The 
stratification factors are disease stage at diagnosis (IIIB vs. IV), response in Induction (CR/PR 
vs. SD), and ECOG performance status (0 vs. 1) after Induction. Refer to the pooling of sparse stratums below for situations in which the full stratified analysis will be replaced by a pooled 
stratified analysis due to a lack of information which could adversely affect power and modeling 
estimation.
The PFS rates, including two-sided 95% confide nce intervals, will be provided for every 2 
months relative to randomization (Greenwoodâ€™s formula, Klein , 2003). Kaplan-Meier curves will 
be provided by [CONTACT_94535]. The associ ated HR and two-sided 95% confidence interval will be 
estimated by [CONTACT_2329] a stratified Cox proportional hazard model, with the same stratification 
factors ( Cox, 1972). Refer to the pooling of sparse stratums below for situations in which the full 
stratified analysis will be replaced by a pooled stratified analysis due to a lack of information which could adversely affect power and modeling estimation.
Pooling Algorithm for Eliminating Sparse Stratums
If there exists unacceptable sparseness in some stratum cells for the sm allest treatment arm due 
to the 2:1 randomization ratio (i.e., a stratum cell that has fewer than 5 PFS events for the BSC
treatment arms in the ITT population of the Maintenance part), then an algorithm for eliminating 
some full strata will be employed until there are at least 5 events in any given revised stratum 
cell. The initial stratum cells for the combined  treatment arms will start out as 8 cells that 
represents all possible permutations of the 3 strata (baseline Eastern Cooperative Oncology 
Group [ECOG] performance status at the end of the Induction part [0 vs. 1]; tumor response to 
induction chemotherapy [CR/PR vs. SD]; and disease stage before administration of induction 
therapy [IIIB vs. IV]). Hence, the 8 cells represe nting all possible permutations among the strata 
may be reduced down to either 4 cells (all possible permutations of just 2 relatively large strata), 
2 cells (just 1 large stratum); or no strata at all when implementing the algorithm. However, it is 
extremely unlikely that th e algorithm will result in no stratum. Once the revised strata have been 
determined through this al gorithm, then it w ill be used consistently for all endpoints and 
populations involvi ng a pre-specified stratified analysis.
If a sparse strata cell exists, then first consider all [ADDRESS_833387] stratum cell. 
For example, consider three candidate pooling sets (a, b), (a, c), and (b, c), where set (a, b) has 
event cell counts {(a1, b1), (a1, b2), (a2, b1), (a2, b2)}; set (a, c) has event counts {(a1, c1), (a1, 
c2), (a2, c1), (a2, c2)}; and set (b, c) has event counts {(b1, c1), (b1, c2), (b2, c1), (b2, c2)}. 
Now let (a, b)* = min { (ai, bj) } for i=1, 2 and j=1, 2; and (a, c)* = min { (ai, cj) } for i=1, 2 and &(/*(1([ZIP_CODE],(7$5<,1)250$7,21PR R 
sparse parse 
pooled pooled 
and modeliand model
ded for ded for evereve
Kaplanaplan -MeiM
confidenceonfidenc
the same se sam
w for situaw for situa
ysis due to aysis due to
on.n
msms
e stratum cstratum c
m cell that m cell that
the Maintethe Main
l there are l there 
e comcobinebinem
ions of the ions of the
status at thstatus at th
CR/PR vs. R/PR 
Hence, theHence, the
wn to eithern to either
ge stratum)ge stratum)
ikely that thkely that 
d through ththrough th
onsinvoinvolvilv
If a sparsef a sparse
select thelect t
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 46j=1, 2; and (b, c)* = min { (bi, cj) } for i=1, 2 and j=1, 2. The newly pooled stratum would be a 
two strata combination of a, b, or c that is the maximum of set { (a, b)*, (a, c)*, (b, c)* } for i=1, 
2 and j=1, 2. In the case of tied cases (e.g., (a, c) and (b, c) are both suggested as the two strata to 
be used in the analysis), then priority will be based on what is clinically more relevant to keep.  
If a sparse strata cell s till exists in the first round of pooling, then the a bove pooling process 
would start over again to form a single stratum.  The pooled candi date stratums are now a, b, and
c with the final pooled strata being the max { a* , b*, c* } in which no sparse strata cell exists. In 
selecting the final pooled strata; a* = min{ ai } for i=1, 2; b* = min{ bi } for i=1,2; and c* = min 
{ci } for i=1, 2. Again, in the case of tied cases, (e.g., b and c are both suggested as the strata to 
be used in the analysis), then then priority will be based on what is clinically more relevant to 
keep.
If there still exists a sparse cell, then the primary analysis will default to an unstratified one.For this particular application, a = baseline Eastern Cooperative Oncology Group [ECOG] performance status at the end of the 
Induction part [a1=0 vs. a2=1] strata; 
b = tumor response to induction chemotherapy [b1=CR/PR vs. b2=SD] strata;
c = disease stage before administration of i nduction therapy [c1=IIIB vs. c2=IV]) strata.
In case of ties, clinical priority will be given to stratums a) baseline ECOG at end of Induction 
part; b) tumor response to induction chemotherapy; and c) disease stage before administration of induction therapy in this order (i.e., strata a: baseline ECOG has the highest priority and strata c:
disease stage before administration of induction therapy has the lowest priority). 
Supportive and Sensitivity Analyses
The following analyses will be conducted as supporting or sensitivity analyses using the same 
methods (i.e. p-value from stratified log-rank test, HR and two-sided 95% confidence interval from the stratified Cox model):
!PFS as calculated from Day 1 of treatment for the Induction Part. For this analysis, 
the stratification factors will be the same  as those used in the primary efficacy 
analysis.
!PFS where subsequent anti-cancer th erapy is considered a PFSevent
!To assess the impact on PFS of response assessments not occurring at the regularly 
scheduled assessment times, the frequency of these unscheduled/off-scheduled visits will be presented for each treatment arm. In addition, sensitivity analyses will be performed where subjects with events and censorings that occur at a time other than 
the regularly scheduled visit assessment, will have PFS time based on the date of the 
next regularly scheduled assessment rather than the actual off-schedule date. The methods similar to the primary analysis will be used to estimate the median PFS 
along with HRs.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21min in
ta to to 
vant to nt to 
tratified onratified o
mance statusnce statu
 b2=b2=SD] sSD
y[[yc1=c1=IIIB IIIB
tums tum a) baa) ba
apy; and c) py; and c
baselibaseli ne ECne EC
uctuctioion theran ther
eses
be conductee conducte
stratified ltratified 
mmodelo):
alculated fculated f
ratificatratificat ioion
nalysis.alysis.
PFS whePFS whe
!!To aTo 
sc
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 47!An additional analysis of PFS will be performed using the European Medicines 
Agency methodology for analysis of a PFS endpoint.  Similar to the approach described above, PFS will be defined as the time from the rando mization date to the 
start of disease progression or s ubject death (any cause), wh ichever occurs first. 
Subjects who do not have disease progression or have not died will be censored at the last known time that the subject is progression free (i.e. the last tumor assessment).  
However, occasional missing observation s or initiation of s ubsequent anticancer 
therapy will not result in censoring for this analysis.  
!Sensitivity analyses to address the impact of measurability of endpoints and 
adherence to protocol will be done by [CONTACT_625578].
[IP_ADDRESS]. Analyses of Secondary Efficacy Endpoints7.[IP_ADDRESS]. Overall Survival
Overall survival is defined as the duration in months between rando mization a nd death from any 
cause:
Time to OS = (Day of death or censoringâ€“ Day of randomization + 1)/30.[ADDRESS_833388] prior to or on the cutoff date will be censored at the â€˜last date 
known aliveâ€™. For subjects who have withdrawn consent during the study, the last date known 
alive will be the date of consent withdrawal from the study. For all other subjects, the last date known alive will be the data cutoff date.
Analysis of OS will parallel the analysis of PFS described in Section [IP_ADDRESS] . P-values 
generated from these analyses will only be interpreted if the primary analysis is significant. The p-value for the stratified log-rank test using the ITT population will be considered the main 
analysis for the secondary endpoint, with unstratified analyses and analyses based on per 
protocol and response evaluable populations considered supporting analyses.
Additional supporting and sensitivity analyses will be performed as follows:
!Overall Survival calculated from Day 1 of treatment for the Induction Part (Time to OS = 
Day of death â€“ Day 1 of treatment for the Induction Part + 1),
!Overall survival using the additional censoring rule of Day [ADDRESS_833389] survival, a sensitivity 
analysis will be conducted. Subjects who start a subs equent anti-cancer therapy will be censored 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21d above above 
atatioion and dn and
n + 1)n + 1 /30.[ADDRESS_833390] was aliv
differentdifferent
o or on theo or on the
ve withdrawwithdra
witwithdrawahdrawa
cutoff date.utoff date
llel the anallel the a
analysnalys ees wis wi
ified ed lolog-g-rar
secondarysecondary eyy
response evresponse ev
al supportinsupportin
Overall Overall
DayDay oy
!O
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 48at the initiation date of the subsequent chemotherapy; a method similar to the primary analysis 
will be applied to estimate the medians of OS and compare the survival distributions between 
two treatment arms. 
[IP_ADDRESS].2. Tumor Response and Overall Response Rate
Overall response over the entire study is defined as a complete or partial response (CR/PR) to 
BSC or nab-paclitaxel+BSC based on the baseline established within [ADDRESS_833391] an overall response if there is any tumor 
assessment where the confirmed overall tum or response is â€œComplete Responseâ€ or â€œPartial 
Response.â€ The best response among any tumor assessments after Day [ADDRESS_833392] receives a subsequent anti-cancer therapy will be used 
for this analysis. This will be calculated for randomized subjects only.
The ORR will be summarized by [CONTACT_625579]/PR and 
presented with 95% confidence intervals for the percent. The treatment effect size will be 
estimated by [CONTACT_625580] (P
nab-P+BSC /PBSC). The ORR will be analyzed using the 
Cochran-Mantel-Haenszel (CMH) test with stratification factors:
!Disease stage at diagnosis (IIIB vs. IV); 
!Response in Induction (CR/PR vs. SD); 
!ECOG performance status at end of Induction (0 vs. 1). 
If strata cell sizes are too small based on Mantel-Fleiss criterion, Pearson chi-square test will be 
used instead. This analysis based on the ITT population will be used as the main analysis of ORR.
As sensitivity analyses, a CMH (or Pearson chi-square) test with the above strata will be 
performed on the PP and res ponse evaluabl e populations.
An additional analysis will be performed on the ITT population of ORR in which subjects with a 
best overall response of CR or PR with or without confirmation of response are considered 
responders.
The number and percentage of those with a best overall tumor response over the entire study of 
PD, SD, PR, CR, and unevaluable (UE) will be presented. The denominator for the percentage 
will include all ITT subjects (subjects who were ra ndomized in the Maintenance Part), regardless 
of whether they had a tumor assessment. Subjects  with no tumor assessments will be considered 
UE. This analysis will be presented for each protocol-specified CT scan. If there is more than 
one CT scan within a relative day range, the best response will be counted. Relative study day windows are presented in Section 11.4.
The best (i.e., smallest) percent change from baseline will be calculated for all subjects and will 
be presented by [CONTACT_408910] a waterfall plot.ial al
or theor thef
ill be used ill be used
s wis withtiii CR/PCRh
fect size wfect size w
analyzed uanalyzed
oonn(0 vs. 1)([ADDRESS_833393] (i.ehe best (i.e
be presentbe presen
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary [IP_ADDRESS]. Analyses of Other Secondary Endpoints
[IP_ADDRESS].1. Disease Control Rate
Disease Control rate is defined as the percent of subjects who have a radiologic complete 
response, partial response, or stable disease according to RECIST 1.1 guidelines, as determined 
by [CONTACT_093]. Disease Control rate over the entire study along with associated Clopper-
Pearson 95% CI will be presented for the Maintenance ITT population. The relative treatment effect will be summarized by [CONTACT_625581]-sided 
95% CI.
[IP_ADDRESS].2. Time to Response
Time to confirmed response is defined as th e time from the first day of Induction st udy drug to 
the first occurrence of confirmed response (CR or PR) over the entire study. The time to 
confirmed response will be presented by [CONTACT_625582] s tatistics. Only 
subjects with a confirmed CR or PR as a best overall response will be included in this analysis.
The same analysis will be performed for time to response with or without confirmation of 
response.
[IP_ADDRESS].3. Duration of Response
For subjects who had a confirmed CR or PR, the duration of overall response is measured from 
the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first 
date that recurrent or progressive disease is ra diologically documented (taking as reference for 
progressive disease the smallest measurements recorded on study). 
Subjects who are non-responders (i.e., do not achieve at least a PR) will be excluded from this 
analysis. Subjects who do not have PD after the response will be censored on the date of last 
tumor assessment. If a subject died before PD, then the subject will be censored on the date of death. 
The duration of response will be analyzed us ing the Kaplan-Meier method. The median time 
(including 2-sided 95% CI) will be summarized for each treatment arm; the associated hazard ratio with two-sided 95% confidence interval will be estimated using a stratified Cox 
proportional hazard model ( Cox, 1972). For this an alysis, the stratification factors will be the 
same as those used in the primary efficacy analysis, if stratum sizes are sufficient. 
The same analysis will be performed for duration of response with or without confirmation of 
response.
7.3.12. Subgroup Analyses
PFS, OS, and ORR will all be analyzed within the following subgroups (with subgroup data 
based on the clinical database rather than IVRS). Subgroup factors will not be used as regression 
adjustment covariates for rele vant analyses, but otherwise these analyses will parallel the 
analyses for the endpoint performed on the whole population:
1. Age (< 65 years and â‰¥ 65 years, < 70 years and â‰¥ 70 years, < 75 years and â‰¥ 75 years); 
2. Race (white versus non-white)&(/*(1([ZIP_CODE],(7$5<,1)250$7,21tudytudy drug t drug tyy
time to time t
atiatststics. OnOn
uded in thisuded in thi
hout confirmut confir
of overall of overall 
(whichever(whichever
gigically docucally doc
ecorded on corded on
t achieve att achieve a
ter the respter the resp
fore PD, there PD, th
e analyzed e analyzed 
will be sumwill be sum
confidencenfidence
deldel ((lCoxCox
in the primthe prim
sis will be psis will be 
SubgroSubgr
S, OS, and , OS, and 
based on thased on th
adjdjustmustm
alyl
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 503. ECOG status (0 versus 1) at end of Induction;
4. Sex (male versus female); 
5. Region (North America versus Rest of the World)
6. Stage at diagnosis (IIIB versus IV); 7. Response at the end of Induction (PR/CR versus SD);
8. Subjects with medical history that includes diabetes
If there are less than [ADDRESS_833394] plots will be provided displayin g the HRs and corresponding 95% CIs for each subgroup
for PFS and OS. The overall HRs with 95% CIs will also be provided in forest plots.
7.3.13. Analyses of Exploratory Efficacy Endpoints7.3.13.1. Overall Response Rate in Maintenance Part beyond Response in Induction
Overall response during the Maintenance Part beyond the response to Induction therapy is 
defined as a complete or partial response (CR/PR) based on RECIST 1.1, taking as reference the 
sum of the longest diameters of the target lesions measured at the last tumor assessment before randomization.  For example, if the sum of the l ongest diameters of the target lesions at the last 
CT-scan prior to randomization is [ADDRESS_833395] a â‰¥[ADDRESS_833396] further improvement during the Maintenance Part according to this 
definition.  
The target lesions identified prior to the start of Induction therapy will be retained as the target 
lesions for this exploratory analysis.  All subjects who enter the Maintenance Part in each treatment arm will be counted in the denominator of this analysis.    
The percentage of subjects achieving partial response, complete response, and either partial or 
complete response (ORR) as defined above will each be presented with the associated 95% confidence interval.
[IP_ADDRESS]. Tumor Characteristics
The following analyses will be covered under a separate SAP:
!The correlation between pretreatment tumor characteristics and response and 
resistance to the study treatment determined using next-generation sequencing 
methods, immunohistochemistry, or other analysis methods.
!The association between the changes in tumor characteristics and the acquisition of 
resistance to therapy from plasma samples taken at treatment failure during 
Maintenance.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21group, roup, 
h subgrouph subgroup
ots.s.
sponse in ponse in I
e to Inductito Induct
CIST 1.1, tCIST 1.1, t
t the last tut the last t
ameters of tmeters of t
ject will haject will ha
er for the suer for the 
lesiolesio ns andns an
onsonse or stabe or stab
ent during tnt during 
the start ofthe start 
sis.  All subsis.  All su
in the denon the den
s achievingchieving
RR) as definR) as defi
mor Charamor Cha
wing analyseng analyse
!!The cohe co
resres
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 51!The relationships between variants in subject pharmacogenomics, such as 
polymorphisms in enzymes involved in drug metabolism, and treatment efficacy and toxicity.
[IP_ADDRESS]. Healthcare Resource Utilization
Summary statistics for location of care (number of office visits, hospi[INVESTIGATOR_110563], 
hospi[INVESTIGATOR_625529], emergency room vi sits, home healthcare visits, hospi[INVESTIGATOR_6125], unknown, and 
other utilizations) and provide r (general physician, specialist, nurse practitioner/physician 
assistant, paramedical care, unknown, and other) will be presented by [CONTACT_625583] (i.e . Day 1 of every cycle and Early Treatment 
Discontinuation/End of Cycle 4 during Induction, Day 1 of every cycle and disease progression 
during Maintenance Part of study).
7.3.14. Safety Analysis
The purpose of this section is to define the safety parameters for the Maintenance Part. All 
summaries of safety data will be conducted using the safety population. 
[IP_ADDRESS]. Adverse Events
Adverse events will be analyzed in terms of treatment-emergent adverse events (TEAEs), which 
are defined as any AEs that begin or worsen after the randomization date and through 28 days 
after the treatment discontinuation date. In additi on, any SAE with an onset date more than 28 
days after treatment discontinuation date that is assessed by [CONTACT_625584] a TEAE. All AEs will be coded using the Medical Dictionary for 
Regulatory Affairs
Â® (MedDRA) dictionary Version 17.0 or higher. The severity will be graded 
based on NCI CTCAE Version 4.0.
The following rules will be implemented for cycle calculations:
!TEAEs which start after randomization date and on or before Cycle 6 Day 1 belong to 
only Cycle 5.
!TEAEs will be categorized by [CONTACT_941] â€œthrow-back ruleâ€, that is, AEs that start on Day 1 
of a cycle will be allocated to only the previous cycle.
!All TEAEs which start after Day [ADDRESS_833397] 
cycle.
For the summary of treatment related AEs, a treatment-related TEAE is defined as an adverse 
event which was considered to be related, reported as â€œsuspectedâ€ in eCRF, to nab-paclitaxel. If 
a subject experiences multiple occurrences of the same AE with different relationship to study 
medication categories, the subject w ill be c ounted once, as a relationship category of treatment 
related. AEs with a missing relationship will be pre sented in the summary table as a relationship 
category of â€œtreatment-r elatedâ€.
The summaries below will be presented for the Maintenance Part of the study and based on the 
safety population.
If a subject experiences the same AE more than once with different toxicity grade, then the event 
with the highest grade will be tabulated in â€œby [CONTACT_479]â€ tables. If a subject experiences multiple time tim
ogression gression 
enance Parenance Par
ent adverseent advers
omization mization d
yySSAE wiAE wi thtiii
ssed by [CONTACT_625585] 1 1nn7.07.0
d for cyd for cy cle cl
randomizaandomiz
ategorized bategorize
be allallocateo
s which s which sts
aryryofofyy treattreaff
h was conswas cons
experiencperien
catcatioion caten cat
ated. AEs ted. AEs 
categoryategory ooyy
he suhe s
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 52AEs under the same preferred term (system organ class), then the subject will be counted only 
once for that preferred term (system organ class). In addition, AEs with a missing intensity will 
be presented in the summary table as an intensity category of â€œMissing.â€ 
The incidence of TEAEs will be summarized by  [CONTACT_11189] (SOC) and 
preferred term (PT). The intensity of AEs will be graded 1 to 5 according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. For all other 
AEs not described in the CTCAE criteria, the intensity will be assessed by [CONTACT_27414] (grade 1), moderate (grade 2), severe (grade 3), life-threatening (grade 4) or death (grade 5). 
Tables summarizing the incidence of TEAEs by [CONTACT_625586]:
!Overall summary of TEAEs;
!TEAEs presented by [CONTACT_11189], preferred term and worst CTCAE 
grade;
!Treatment-related TEAEs by [CONTACT_625556] (grade 1-2 vs. grade 3-4 vs. grade 5; 
overall and by [CONTACT_5265]);
!Serious TEAE by [CONTACT_625557];
!Treatment-related serious TEAE by [CONTACT_625557];
!TEAEs with action of study drug withdrawn;
!Treatment-related TEAEs with action of study drug withdrawn;
!TEAEs with action of study drug dose reduced or interrupted;
!Treatment-related TEAEs with action of study  drug dose reduced or interrupted;
!TEAEs that lead to death;
!Treatment-related TEAEs with fatal outcome;
!All death within 28 days of treatment discontinuation date with cause of death; 
!Most frequent TEAEs ( â‰¥ 5% in either arm; sorted by [CONTACT_11702], without SOC)
!TEAEs for the following baseline subgroups (provided the number of subjects are 
sufficient): 
#Age (<65 versus 65 to â‰¤74 years versus â‰¥ 75 years)
#Sex (Male versus Female)
All TEAEs will be listed. A listing for non-treatment-emergent AEs will also be provided. 
[IP_ADDRESS]. Peripheral Neuropathy
Peripheral neuropathy events will be collected  in the Physician Assessment of Peripheral 
Neuropathy eCRF and reported as AEs. PN AEs will be included in analyses described in 
Section [IP_ADDRESS] . A summary of PN grade by [CONTACT_625587]. In addition, time from first dose in Induction to the first occurrence or worsening 5). 5). 
ft h e  the 
d worst CTd worst CT
ade 3de 3--4 vs. 4
E grade;E grade;
studytudy ddyrug ru
e reduced oreduced o
ttioion of stun of stu
s  with with fatfata
days odays o f ftretre
TEAEs ( EAEs ( â‰¥ 5â‰¥
he fohe fo llowiw
t): :
AgeAge (<65 v(<65 v
Sex (Sex ( MM
AAEs will beEs will b
[IP_ADDRESS].14.2. PP
PeriPerpherphei
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 53of peripheral neuropathy and time from occurrence or worsening to improvement in peripheral 
neuropathy will be presented by [CONTACT_625588] h the AE data and the PN eCRF data as 
follows:
!Time to first onset of grade 3 or higher peripheral neuropathy;
!Time to improvement of grade [ADDRESS_833398] 1 grade; 
and
!Time to improvement of grade [ADDRESS_833399] is evaluated for adverse events. Kaplan Meier methods will be used to attain the 
median and 95% confidence interval.
[IP_ADDRESS]. Adverse Events of Special Interest
The following summaries will be provided for TEAEs included in the above-mentioned AEs of 
interest: 
1. TEAEs by [CONTACT_372153]; 2. Serious TEAEs; 
3. TEAEs with action of treatment discontinuation;
4. TEAEs with action of dose reduction or interruption;  5. TEAEs with fatal outcome;
In addition, time from first dose in Induction to the first occurrence or worsening of 
Myelosuppression and Peripheral Neuropathy a nd time from occurrence or worsening to 
improvement in Myelosuppression and Periphe ral Neuropathy will be presented by [CONTACT_625589]:
!Time to first onset of grade 3 or AESI;
!Time to improvement of grade [ADDRESS_833400] 1 grade; and
!Time to improvement of grade [ADDRESS_833401] &(/*(1([ZIP_CODE],(7$5<,1)250$7,21ade ade 
thh
yyofofyy the  the ff
l neuropathl neuropat
nsored at thsored 
ll be used tol be used t
cluded in thluded in th
scontinuaticontinuati
uctiuctiononor ii
e;e;
se in Inducse in Indu
ripheral Neheral Nei
osuppressisuppressi o
me to fire to fir st st
Time to iTime to i
!!TimeTim
Due to the sDue to the s&descriptdescrip ii
hereh
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 54is evaluated for adverse events. Kaplan Meier methods will be used to attain the median and 95% 
confidence interval.
AESIs will be listed.
[IP_ADDRESS]. Clinical Laboratory Evaluations
[IP_ADDRESS].1. Hematology
All hematology data will be listed.
[IP_ADDRESS].2. Clinical Chemistry
All clinical chemistry data will be listed.
7.3.15. Quality of Life Analysis
The LCSS and EQ-5D-5L, as described in Section 7.2.12 , will be administered in the 
Maintenance Part of the study as well. Baseline scores are defined as scores captured on Day 1 of 
Induction.
[IP_ADDRESS]. LCSS
LCSS scores (overall constitutional score, symptom burden index, respi[INVESTIGATOR_428818], 3-
item scale) will be calculated in th e same way as described in Section [IP_ADDRESS] .
Summary statistics of the individual LCSS items and summary scale scores, the change from 
baseline, and percent change from base line for these scores will be summarized by [CONTACT_625590], i.e. 
Day [ADDRESS_833402] not reached that point at an interim analysis, will be 
presented. 
Statistical comparisons will be  made between the BSC and nab-paclitaxel +BSC groups in the 
Maintenance Part for change from baseline to last administration in Maintenance using analysis 
of covariance. Disease stage, ECOG status, and response during Induction will be the covariates.
[IP_ADDRESS]. EQ-5D-5L
EQ-5D scores will be calculated in the same way as described for Baseline scores and are 
defined as the score captured on Day [ADDRESS_833403] not reached that point at an interim analysis will be presented.ered ered in the in the
ores capturees cap
index, respi[INVESTIGATOR_625530], resp
d in Sectid in Secti o
summarysummar y
se scores se scores w
rtrttime poitime po
e frome from bbmasease
ce bece be tweentween
continuatontinuat ii
e notnoreachreac
be made bebe made 
nge fronge fro m b
stage, ECstage, EC OO
D-D-5L5L
es will be cas will be ca
the score che score c
d.d.
e utilitutilit y yscosco
utilitutilit y yscorscor
populopulatati
in
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 55Summaries of the VAS (with the exception of the missing values) results, the change from 
baseline, and percent change from baseline will be presented for every time point at which the 
instrument is given. In additio n, the change from baseline to the last reported overall score 
during the Maintenance Part, either the disease progression or early discontinuation visit or the last reported overall score before clinical cutoff for subjects who have not reached that point at 
an interim analysis will be presented.
Shifts from baseline to each time point at which the instrument is given will be presented for 
each dimension of the EQ-5D-5L for the ITT population. 
For the utility score and the VAS, statistical comparisons will be made between the BSC and 
nab-paclitaxel+BSC groups in the Maintenance Part for change from baseline to last 
administration in Maintenance using analysis of covariance. Disease stage, ECOG status, and 
response during Induction will be the covariates. 
7.4. Follow-up
First subsequent systemic anti-cancer reg imens will be summarized by [CONTACT_2939]. 
To assess how quickly the second line therapy will be initiated for the subjects who discontinued 
the study treatment, the time to first subsequent therapy, defined as the time interval from the 
date of treatment discontinuation to the start date of the first subsequent anti-cancer regimen. The start date of the first subsequent anti-cancer regimen is the earliest start date of any anti-cancer 
therapy taken in the follow-up/survival period. Subjects who donâ€™t have a subsequent therapy 
and have not died as of the cutoff date for the statistical analysis will be censored at the last follow up date. Subjects who die before initiating a subsequent therapy will be censored at the 
date of death.
The time to second line therapy will be analyzed using the Kaplan-Meier method. The median 
time (including 2-sided 95% CI) will be summarized for each treatment arm; the associated 
hazard ratio with two-sided 95% confidence interval will be estimated using the Cox 
proportional hazard model (Cox, 1972).
In addition, first subsequent anti-cancer tr eatment regimens will be summarized by [CONTACT_625591]; the number of cycles
overall, and the number of cycles for each regimen category and regimen administered. The best response overall and for each regimen category and regimen administered will be summarized. 
Treatment duration, defined as (date of last dose of any tr eatment in a reg imen - date of first dose 
of any treatment in the same regimen) + 1 will be  summarized as well. Additional subsequent 
anti-cancer treatment regimens will be listed.
Anti-cancer surgeries during follow-up will be summarized by [CONTACT_625592]-up surgeries will be listed.
Radiation therapy during follow-up will be su mmarized by [CONTACT_2939] a nd by [CONTACT_17203] (prior, 
concomitant, follow up); type (External beam, radio-immuno therapy, brachytherapy, other);
location (if external b eam); dose; fraction; intent (adjuvant, curative, palliative, unknown); and 
setting (stand alone radiation therapy, concurrent with other anti-cancer therapy, sequential to 
other anti-cancer therapy). Follow-up radiation therapy will be listed.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21nd 
atus, and atus, and
reatmatment aen
he subjectsubject s
as thte timem
ubsequent ubsequen
earliest stararliest st
who donâ€™t who don
cal analysiscal analysis
a subsequea subseque
lyzed usingyzed usin
summarizesummari
fidence intefidence 
972).972)
nti-i-cancer cancer t
receiving eeceiving 
of cycles of cycles fo
for each for each regr
n, defined a, defined a
t in the samt in the sam
reatment rereatment re
ncer surgeri surger
class and pclass and 
Radiation thRadiation th
concomitoncomit
caticatioo
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833404] limit estimates. All data for patients not 
experiencing a PFS event may not be totally clean as of the December 12thcut-off date.     
8.2. Statistical Approaches for Control of Alpha
There will be one non-binding interim analysis for futility for the primary endpoint, PFS, when approximately 91 events (67% infor mation) have been observed. Fut ility may be d eclared and 
the study discontinued if the conditional pow er at the interim analysis is < 10%. The final 
analysis of PFS will be performed when approximately [ADDRESS_833405] been observed.
A Step-down procedure from PFS to OS will be used to control the family-wise two-sided Type-
I error rate to 5%. That is, OS will be tested only if the nab-paclitaxel plus BSC regimen 
demonstrates superiority over the BSC alone with PFS.
The marginal significance level for OS will be adjusted according to O'Brien-Fleming type of 
boundary. The nominal two-sided p-values for d eclaring superiority will be calculated using the 
statist ical software  The analysis and boundaries will be adjusted 
based on the actual number of deaths observed. 
There will be two analyses for the secondary OS endpoint. The interim analysis of OS will be 
conducted based on the number of deaths observed up to the clinical cutoff date. Fut ility may be 
declared and the study discontinue d if the conditional power at the interim analysis for OS is < 
10% or the nab-paclitaxel plus BSC regimen does not demonstrate superiority over the BSC 
alone with PFS. For efficacy, the two-sided nominal value p-value stoppi[INVESTIGATOR_625531] 0.009. Efficacy will be declared and study discontinued if p-value crosses stoppi[INVESTIGATOR_625532]-paclitaxel plus BSC regimen demonstrates superiority over the 
BSC alone with PFS. If neither futility nor eff icacy is declared at the interim analysis of OS, the &(/*(1(e 
tual numbtual num
be two anabe two ana
ted based oed based o
ared and theared and th
0%%or or ththe e n
allone wione wi ththiii
ntnt1([ZIP_CODE],(7$5<,1)250$7,21e 
willillbe be 
atioions will bns will
nbinding.binding.
cttioion win withthiitthh
for the intr the i
provided inrovided in
xpected to pected to o
nalyzed nalyze ag
ststimates. imates. AA
hhe Decembe Decemb
rol of Alprol of Alp
s for futilits for futilit
) have beenhave been
power at thpower a
hen approxien appr
S to OS wilS to OS w
will be testwill be tes
er the BSCer the BS
nce lnce l evelevel ffllof
nalal twotwol -sidsi
erimerim(1(
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833406] Ratio (HR) <0.85. 
In the stratified Cox proportional hazard model,  denote the Log(Hazard Ratio) parameter as 
 .
The estimated Log(HR) at the interim analysis approximately has a normal distribution
, where 
 is the estimator for the hazard ratio (HR) on the natural log scale with mean 
and variance
 . So the probability of clinically meaningful PFS effects is
,
where 
 and 
 is the estimated hazard ratio on the natural log scale 
with standard error 
 . 
and 
 are readily available on SAS Proc PHREG output. The 
hazard ratio of 0.[ADDRESS_833407]. Other probabilities 
of meaningful HRs that may represent stronger PFS effects will also be provided (e.g.,
))60.0log(Ë†Pr()),70.0log(Ë†Pr()),75.0log(Ë†Pr()),80.0log(Ë†Pr( âˆƒ âˆƒ âˆƒ âˆƒ % % % % ). .
8.4. Conditional Power at the Interim Analysis for PFS
The two-sided conditional power for PFS at the interim analysis is computed as 
(Jennison and Turnbull (2000) Page 205-208)
where
(the log hazard ratio under the alternative 
hypothesis);
: the unstratified log-rank test statistic computed from the observed data at the interim;
: the information level at the interim stage, 
 ;
: the number of PFS events at the interim stage;
: the proportion of the subjects randomized to nab+BSC arm;
: the information level at the end of the study, 
 ;
: the total number of events at the end of study (136);
: 1.96.
More details about sequential trial design can be found in Lan and DeMets 1983; Lan and Zucker 
1993; Jennison and Turnbull 2000.
Conditional Power depends on the observed test statistic
 and the alternative hypothesis 
 .T h e  
following graph shows the relationship between the observed hazard ratio and the conditional 
power at the interim analysis under different assumptions of alternative hypothesis.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21.
with mean with mean
naturanatur l loog
PHREG ouPHREG ou
effect. Otheffect. Oth
bebeprovideprovid
)))60.00og(g ))
alysisalysis for for
rim analysirim analy
,(
55-208)-208)
nk test statitest stati
el at the inteel at the in
FS events aS events 
n of the subn of the sub
attioion n level leve
number ofnumber of
e details abe details ab
993; Jennis993; Jenni
&CondiCondi titiiio
lolw
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 58               
2EVHUYHG+5DWWKHLQWHULP&RQGLWLRQDO3RZHU++5 
++5 
++5 
++5 
++5 Conditional Power vs observed HR 
 Total 136, interim 91 
 HR: nab-P+BSC vs BSC
The plot above shows the relationship of the conditional power and the observed hazard ratio at 
the interim based upon the assumed unkown true hazard ratio. The light green hashed line is the 
assumed true hazard ratio of 0.60 which was used in determining the 136 PFS events required to 
provide 80% power under a two sided test at the nominal 5% level of significance). 
Operating charatceristics for stoppi[INVESTIGATOR_625533]/ observed hazard ratios based upon 5,[ADDRESS_833408] ratio of 0.60 are provided in the tables below.
Observed HR at Interim Conditional Power based on the observed HR 
and the assumption that the true HR=0.6
1.00 3.7%
0.98 5%
0.94 10%
0.89 15%
Futility Criteria Percentage of declaring futility at Interim 
given the true HR=0.6
HR>1.00 1.0%
HR>0.98 1.3%
HR>0.94 2.1%
HR>0.89 3.7%&(/FuFu(/*(1([ZIP_CODE],(7$5<,1)250$7,21,1<,1,1,1,1,[ADDRESS_833409] ratio
sed in detered in dete
the nominthe nomin
the estudystudy ata
ratios baseratios bas
ofof 0.60 are0.60 arff
erimerim35
00( 0.98.981(0.940.94(10.890.89(1*(
(/&(&
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 598.5. Conditional Power at the Interim Analysis for OS
Interim Analysis for OS will be conducted when 136 PFS events are achieved and the 
nab-paclitaxel plus BSC regimen demonstrates s uperiority over the BSC alone with PFS.
Otherwise, OS will not be tested and therefore there will not be an interim analysis for OS.
The two-sided conditional power for OS at the interim analysis is computed as
(Jennison and Turnbull (2000) Page 205-208)
where
(the log hazard ratio under the alternative hypothesis
for OS);
: the unstratified log-rank test statistic of OS computed from the observed data at the interim;
: the information level at the interim stage, 
 ;
: the number of OS events at the interim stage;
: the proportion of the subjects randomized to nab+BSC arm;
: the information level at the end of the study, 
 ;
: the total number of OS events 1.5 y ears after final analysis of PFS (147);
: 1.96.
Conditional Power depends on the observed test statistic 
 and the alternative hypothesis 
 . The 
following graph shows the relationship between the observed hazard ratio and the conditional power at the interim analysis of OS under different assumptions of alternative hypothesis, in 
which the assumption is that the number of OS events in the interim analysis is 92.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21rnatnative hypi[INVESTIGATOR_625534]
;;
;;
alysis of PFysis of P
statisttatist ic 
n the obsethe obse
different assfferent as
of OS eveof OS ev
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 60        
2EVHUYHG+5DWWKHLQWHULP&RQGLWLRQDO3RZHU++5 
++5 
++5 
++5 
++5 
++5 Conditional Power vs observed HR 
 Total 147, interim 92 
 HR: nab-P+BSC vs BSC
The plot above shows the relationship of the conditional power and the observed hazard ratio at 
the interim based upon the assumed unkown true hazard ratio. Th e purple hashed line is the 
assumed true hazard ratio of 0.70 which was used in determining the 147 OS events required to 
provide 53%  power under a two sided test at the nominal 5% level of significance). 
Operating charatceristics for stoppi[INVESTIGATOR_625533]/ observed hazard ratios based upon 5,[ADDRESS_833410] ratio of 0.70 are provided in the tables below.
Observed HR at Interim Conditional Power based on the observed HR 
and the assumption that the true HR=0.7
1.00 2.5%
0.95 5%
0.89 10%
0.85 15%
Futility Criteria Percentage of d eclaring fut ility at Interim 
given the true HR=0.7
HR>1.00 5.2%
HR>0.95 8.0%
HR>0.89 13.4%
HR>0.85 18.3%&(/*(1([ZIP_CODE],(7$5<,1)250$7,21<5<5<,1)QWHULPQWHULP<<<<,<
titionalonal powpowll
ue hazard rae hazard 
used in deused in de
t at the nomt at the nom
ng the studyg the stud
ard ratios bard ratios b
io ofo of 0.7 0.7ff00
InterimInterim3
.00.001(0.950.9510.890.89(10.80.8*(/*(&
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 619. CHANGES TO THE STATISTICAL ANALYSES SECTION OF 
THE PROTOCOL
For the Induction Part, the following changes were made to the secondary efficacy endpoints:
!Disease control rate: protocol originally stated DCR over the enti re study, statistical 
analysis plan is adding text to clarify DCR will also be analyzed separately during Induction Part
For the Maintenance Part, the following changes were made to the secondary efficacy endpoints:
!PFS from Day 1 Cycle 1, protocol originally stated PFS from randomization into the 
Maintenance Part of the study, statistical analysis plan is adding additional analyses to 
further characterize the PFS endpoint;
!OS from Day 1 Cycle 1, protocol originally stated OS from rando mization into the 
Maintenance Part of the study, statistical analysis plan is adding additional analyses to further characterize the PFS endpoint;
!ORR without confirmation required for PR or CR: protocol originally stated ORR during 
Induction and Maintenance Parts, statistical analysi s plan is adding additional analyses to 
further characterize the ORR endpoint.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ndpondpo intints:s
nintinto the o the 
al al analysesanalyses
mizatmizat ioion in
g additg addit ioionan
ocol originocol or
plan is addplan is add
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-[ADDRESS_833411]. Regression Models and Life-Tables. Journ al of the Royal Stati stical Society. Series B
(Methodological). 1972, 34 (2): 187â€“ 220.
Klein JP and Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated
Data, 2nd ed. Springer, 2003.
Mantel N and Fleiss JL (1980). Minimum Expected Cell Size Requirements for the Mantel-
Haenszel One-Degree-of-Freedom Chi-Square Test and a Related Rapid Procedure. American 
Journal of Epi[INVESTIGATOR_623], 112: 129-134.
Lan and DeMets (1983). Discrete Sequential Boundaries for Clinical Trials. 
Biometrika (1983) 70 (3): 659- 663.
Lan and Zucker (1993). Sequential Monitoring of Clinical Trials: The Role of Inform ation and 
Brownian Motion. Statistics in Medicine 12(8):753 - 765
Jennison and Turnbull (2000). Group Sequential Methods with Applications to Clinical Trials. 
CRC/Chapman & Hall, U.K., 2000.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21erican ican 
Role oe of fInfoIn
ApplicatApplic io
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 6311. APPENDICES
11.1. Study schematic
11.2. Handling of Dates
Dates will be stored as numeric variables in the SAS analysis files and reported in 
DDMMMYYYY format (i.e., the Date9. datetime format in SAS).  Dates in the clinical database 
are classified into the categories of procedure dates, log dates, milestone dates, outcome dates, and special dates.
!Procedure Dates are the dates on which given protocol-specified procedure are 
performed.  They include the dates of la boratory testing, physical examinations, 
tumor scans, etc. They s hould be present whenever data for a protocol-specified 
procedure are present and should only be missing when a procedure are marked as 
NOT DONE in the database. Procedure dates will not be imputed.
!Log Dates are dates recorded in CRF data logs. Specifically, they are the start and 
end dates for adverse events and concomit ant medications/procedures.  They should 
not be missing unless an event or medication is marked as ongoing in the database.  
f Datesf Date
as numerics numeri
formform at (at (ii
into the catnto the ca
dates.dates.
!!ProceProce
perfper
tt
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 64Otherwise, incomplete log dates will be imputed according to the rules in Appendix 
16.2 (eg, for duration or cycle assignment, etc). However, in listings, log dates will be 
shown as recorded without imputation.
!Milestone Dates are dates of protocol milestones such as rando mization, study drug 
start date, study drug termination date, study closure date, etc.  They should not be 
missing if the milestone occurs for a subject. They will not be imputed.
!Outcome Dates are dates corresponding to study endpoints such as survival, 
progression, etc. In most cases they are derived either from a milestone (eg, the survival date is derived from the death date), or a procedure date (eg, the progression 
date is derived from the date of the tumor scan that was used to determine 
progression). They may be subject to endpoint-specific censoring rules if the outcome did not occur, but are not otherwise subject to imputation.
!Special Dates cannot be classified in any of the above categories and they include the 
date of birth. They may be subject to variable-specific censoring and imputation rules. 
!Last Contact [CONTACT_625593], if the imputed date used for response date or AE date, the last contact [CONTACT_625594].
Dates recorded in comment fields will not be imputed or reported in any specific format. 
11.2.1. Calculation Using Dates
Calculations using dates ( e.g., subjectâ€™s age or relative day after the first dose of study drug) will 
adhere to the following conventions: 
!Study days after the start day of study drug will be calculated as the difference 
between the date of interest and the first date of dosing of study drug plus 1 day. The generalized calculation algorithm for relative day is the following: 
#If TARGET DATE >= DSTART then STUDY DAY = (TARGET DATE â€“
DSTART) + 1; 
#Else use STUDY DAY = TARGET DATE â€“ DSTART.
Note that Study Day [ADDRESS_833412] day of  treatment of study drug. Negative study days 
are reflective of observations obtained during the baseline/screening period. Note: 
Partial dates for the first study drug are not imputed in general. All effort should be 
made to avoid incomplete study drug start dates. 
!Age (expressed in days) is calculated: AGE = CONSENT DATE â€“ DATE of BIRTH 
+ 1.  In practice, age will be transformed to years by [CONTACT_625595] 
365.25 days, then truncating.
#Preference is for using calculated age from clinical database. When not available, 
calculated age from CRF or IVRS may be used
#Partial birth date: impute missing day as 15
thof the month; impute missing month 
as July; set missing age for missing year&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ession ession 
the outcomthe outcom
and theyand they iiyyn
g and impug and impu
mum date cmum date c
AE date, theAE date, t
aximum daaximum da
ported in anorted in an
ative day afative day 
studystudyf drugdruyy
and the find the fi rs
gorithm forgorithm 
TE >= DSTTE >= DST
;;
TUDY DATUDY 
StudyStudy DayDayy
ectective of oive of o
ialaldatedatell ssfo
made made to avoto avo
Age (exAge (e
+ 1. + 1
3636
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 65!Intervals that are presented in weeks will be transformed from days to weeks by [CONTACT_2329] 
(without truncation) the following conversion formula:
WEEKS = DAYS /7
!Intervals that are presented in months will be transformed from days to months by 
[CONTACT_2329] (without truncation) the following conversion formula:
MONTHS = DAYS /30.4375
11.3. Date Imputation Guideline
11.3.1. Impute Missing Dates for Adverse Ev ents/ Prior or Concomitant Medications
Incomplete Start Date
!If the stop date is not missing, and the imputed start date is after the stop date, the 
start date will be imputed by [CONTACT_366854].
Missing day and month
!If the year is the same as the year of the first dosing date, then the day and month of 
the first dosing date will be assigned to the missing f ields.
!If the year is prior to the year of first dosing date, then December 31 will be assigned 
to the missing fields.
!If the year is after the year of first dosing, then January 1 will be assigned to the 
missing fields.
Missing day only 
!If the month and year are the same as the year and month of first dosing date, then the 
first doing date will be assigned to the missing day.
!If either the year of the partial date is before the year of the first dosing date or the 
years of the partial date and the first dosin g date are the same but the month of partial 
date is before the month of the first dosing date, then the last day of the month will be 
assigned to the missing day.
!If either the year of the partial date is after the year of the first dosing date or the 
years of the partial date and the first dose date are the same but the month of partial date is after the month of the first dosing date, then the first day of the month will be 
assigned to the missing day.
Missing day, month, and year
!No imputation is needed, the corresponding AE will be included as TEAE if end date 
of AE is after the first dose date or the end date is also missing. 
Incomplete End Date
Missing day and month
!December 31 will be assigned to the missing fields.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21cationscations
he stop datehe stop date
atee, then the, then th
fields.ields.
atee, then De, then D
gg, then Jan, then Ja
e samesame as tas
signed to thsigned to
he partihe parti alalddll
l date and tl date and t
he emomontnhh
the missinghe missin
r the ythe y ear oear o
s o of fththe parte par
teis is afterafter
assigned tassigned t
issing day, issing day, 
!!NN
com
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 66Missing day only 
!The last day of the month will be assigned to the missing day. 
11.3.2. Impute Missing Dates for Medical History
Partially missing medical history start dates will be imputed in the derived dataset for medical 
history. The 16thof the month will be used to impute a partially missing start date that has only 
the day missing, and July 1stwill be used to impute a partially missing start date that has both the 
month and day missing.
11.4. Tumor Response Windows
Relative Day Ranges for the CT-Scans
Study 
WeekStudy Part Relative Weeks 
in 
Study PartRelative Days in 
Study Part
6 Induction 6 2 - 63
12 12 â‰¥64 and before 
randomization
18 Maintenance 6 2 - 63
24 12 64 - 105
30 18 106 - 147
36 24 148 - 189
42 30 190 - 231
48 36 232 - 273
54 42 274 - 315
60 48 316 - 357
66 54 358 - 399
72 60 400 - 441
78 66 442 - 483
84 72 484 - 525
90 78 526 - 567
96 84 568 - 609
102 90 610 - 651
108 96 652 - 693
114 102 694 - 735
120 108 736 - 777
126 114 778 - 819
132 120 820 - 861
138 126 862 - 903&(/*(1([ZIP_CODE],(7$5<,1)250$7,21he he 
e Days in e Days in
udy Partudy Part2555
2 - 62 - 61â‰¥64â‰¥64anan
ran,1
5<5<5<5<6$5555
1217$1818(7$22(7555,(5555
3333 7878333
8484([ZIP_CODE]((19(1(1(1(((
nab-Paclitaxel (AbraxaneÂ®)
Statistical Analysis Plan. Protocol ABI- 007-NSCL-003 Celgene Corporation
Confidential and Propri etary 6711.5. MedDRA Versions and Dates
For reports dated: MedDRA version
05May2014 â€“ 01Nov2014 17.0
02Nov2014 â€“ 03May2015 17.1
04May2015 â€“ 01Nov2015 18.0
02Nov2015 â€“ present 18.1
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21